<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10767932</article-id>
    <article-id pub-id-type="pmid">37831083</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad832</article-id>
    <article-id pub-id-type="publisher-id">gkad832</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>PharmGWAS: a GWAS-based knowledgebase for drug repurposing</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9581-1329</contrib-id>
        <name>
          <surname>Kang</surname>
          <given-names>Hongen</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing</addr-line> 100049, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Pan</surname>
          <given-names>Siyu</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing</addr-line> 100049, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lin</surname>
          <given-names>Shiqi</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing</addr-line> 100049, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Yin-Ying</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3614-2441</contrib-id>
        <name>
          <surname>Yuan</surname>
          <given-names>Na</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4523-4153</contrib-id>
        <name>
          <surname>Jia</surname>
          <given-names>Peilin</given-names>
        </name>
        <!--pjia@big.ac.cn-->
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing</addr-line> 100049, <country country="CN">China</country></aff>
        <aff><institution>National Genomics Data Center, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 10 84097798; Email: <email>pjia@big.ac.cn</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-10-13">
      <day>13</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>13</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <volume>52</volume>
    <issue>D1</issue>
    <fpage>D972</fpage>
    <lpage>D979</lpage>
    <history>
      <date date-type="accepted">
        <day>21</day>
        <month>9</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>9</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>14</day>
        <month>8</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad832.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Leveraging genetics insights to promote drug repurposing has become a promising and active strategy in pharmacology. Indeed, among the 50 drugs approved by FDA in 2021, two-thirds have genetically supported evidence. In this regard, the increasing amount of widely available genome-wide association studies (GWAS) datasets have provided substantial opportunities for drug repurposing based on genetics discoveries. Here, we developed PharmGWAS, a comprehensive knowledgebase designed to identify candidate drugs through the integration of GWAS data. PharmGWAS focuses on novel connections between diseases and small-molecule compounds derived using a reverse relationship between the genetically-regulated expression signature and the drug-induced signature. Specifically, we collected and processed 1929 GWAS datasets across a diverse spectrum of diseases and 724 485 perturbation signatures pertaining to a substantial 33609 molecular compounds. To obtain reliable and robust predictions for the reverse connections, we implemented six distinct connectivity methods. In the current version, PharmGWAS deposits a total of 740 227 genetically-informed disease-drug pairs derived from drug-perturbation signatures, presenting a valuable and comprehensive catalog. Further equipped with its user-friendly web design, PharmGWAS is expected to greatly aid the discovery of novel drugs, the exploration of drug combination therapies and the identification of drug resistance or side effects. PharmGWAS is available at <ext-link xlink:href="https://ngdc.cncb.ac.cn/pharmgwas" ext-link-type="uri">https://ngdc.cncb.ac.cn/pharmgwas</ext-link>.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkad832figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32270706</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Strategic Priority Research Program of the Chinese Academy of Sciences</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Startup Research Fund of Henan Academy of Sciences</institution>
          </institution-wrap>
        </funding-source>
        <award-id>232016009</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>The development of novel drugs is a daunting and time- and cost-consuming process, which severely impedes the translation of scientific breakthroughs into clinical applications (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). To address this challenge, drug repurposing, also known as drug repositioning, has emerged as a promising strategy. Drug repurposing seeks to identify novel clinical applications for existing medications or drugs, offering accelerated timelines, reduced risks and lower expenses compared to the traditional de novo drug discovery pipeline.</p>
    <p>Diverse computational approaches have been developed to aid the identification of repurposing candidates, such as signature matching, molecular docking and retrospective clinical analysis and so on (<xref rid="B3" ref-type="bibr">3</xref>). Among these, the signature matching approach, also called the connectivity approach, has been proven particularly effective in discovering new drug repurposing candidates across a wide spectrum of therapeutic domains, even at the level of single-cell resolution (<xref rid="B4" ref-type="bibr">4–10</xref>). It usually involves the comparison of the signature of a drug, often derived through differential gene expression analysis before and after drug treatment, with that of another disease phenotype. The degree of inverse correlation between the two signatures can provide insights into whether the drug may revert the disease phenotype itself. Specifically, representative signature-based methods, or connectivity methods, included the Connectivity Score, which was based on Kolmogorov-Smirnov (KS) statistics and was first implemented by the Connectivity Map (CMap) project (<xref rid="B11" ref-type="bibr">11</xref>). Later, other methods were reported not only measuring the strength of the inverse connections but also assessing the statistical significance of the connections (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>), such as the Connection Strength Score (CSS) and eXtreme sum (XSum) score.</p>
    <p>Recently, advances in genome-wide association studies (GWAS) have revealed important biological insights into complex diseases. These genetics discoveries can assist in identifying compounds suitable for tailored treatments to the respective diseases (<xref rid="B14" ref-type="bibr">14–16</xref>). Indeed, among the 50 drugs approved by FDA in 2021, two-thirds have genetically supported evidence (<xref rid="B17" ref-type="bibr">17</xref>). Traditionally, GWAS signals may provide opportunities for selecting candidate drug targets by identifying the causal variants and genes with large effect sizes (<xref rid="B18" ref-type="bibr">18–20</xref>). For example, IL23R was identified by GWAS as a repurposing candidate for Crohn's disease (<xref rid="B21" ref-type="bibr">21</xref>), and the corresponding drug, ustekinumab, had been shown to have a significant therapeutic effect on IL23R (<xref rid="B22" ref-type="bibr">22</xref>). However, the majority of significant variants are located in the non-coding regions of the genome, making it quite challenging to identify the causal genes. Furthermore, the majority of common variants identified in GWAS had small to modest individual effects on traits, which may not be substantial enough for therapeutic intervention. On the contrary, the combined polygenic effect of many such variants could be considerably large and constitute a significant portion of the overall trait heritability (<xref rid="B23" ref-type="bibr">23–26</xref>). To leverage the discovery power of the vast majority of common variants, GWAS summary statistics can be used to impute the genetically regulated expression (GReX) profile and then compare with the drug-induced gene expression profiles, such as those generated by the Connectivity Map project (<xref rid="B11" ref-type="bibr">11</xref>). Such extended signature matching strategies had been successfully applied in psychiatric disorders (<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>), blood traits (<xref rid="B29" ref-type="bibr">29</xref>) among others. However, there is still a lack of a systematic and comprehensive knowledgebase for genetically-informed drug repurposing for a wide range of complex diseases.</p>
    <p>To address this issue, we developed PharmGWAS, a knowledgebase for GWAS-informed drug repurposing across a diverse spectrum of diseases. We constructed a standard computational inference workflow to first implement the transcriptome-wide association study (TWAS) strategy and impute the GReX signatures in disease-relevant tissues for each GWAS dataset. We also curated a comprehensive list of drug-induced gene expression profiles from the CMap project and the Gene Expression Omnibus (GEO) database (<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>). We then implemented six computational methods to search for the drug-induced signatures that had a negative correlation with the GReX signature. These methods have been well-reported and evaluated in literature to successfully connect diseases and candidate drugs. PharmGWAS thus provides a valuable reference resource by leveraging genetic evidence to aid the discovery of novel drugs, the exploration of drug combination therapies and the identification of drug resistance or side effects.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Data collection</title>
      <p><italic toggle="yes">GWAS summary statistics</italic>. We downloaded GWAS summary statistics mainly from three sources: GWAS Catalog (<xref rid="B32" ref-type="bibr">32</xref>), UK BioBank (UKBB) (<xref rid="B33" ref-type="bibr">33</xref>) and large consortiums dedicated to diverse diseases, including Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) Genetics Consortium (<xref rid="B34" ref-type="bibr">34</xref>), Cerebrovascular Disease Knowledge Portal/International Stroke Genetics Consortium (CDKP/ISGC) (<xref rid="B35" ref-type="bibr">35</xref>), Common Metabolic Diseases Knowledge Portal (CMDKP) (<xref rid="B36" ref-type="bibr">36</xref>), Cardiovascular Disease Knowledge Portal (CVDKP) (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>), Reproductive Genetics Consortium (RGC) (<xref rid="B39" ref-type="bibr">39</xref>), Psychiatric Genomic Consortium (PGC) (<xref rid="B40" ref-type="bibr">40</xref>) and Sleep Disorder Knowledge Portal (SDKP) (<xref rid="B41" ref-type="bibr">41</xref>). According to the Experimental Factor Ontology (EFO) provided by GWAS Catalog, we filtered out the GWAS data where the trait description did not map to the disease terms in the EFO. Also, we only retained disease-related GWAS data for UKBB according to the international classification of diseases (ICD-10), cancer code and non-cancer illness code. Considering that the TWAS prediction models were built based on reference data of European ancestry (<xref rid="B42" ref-type="bibr">42</xref>), we only kept the GWAS data from European ancestry in our current version of PharmGWAS. Redundant datasets were removed. We also collected metadata such as sample size, ancestry and release year of the datasets from GWAS Catalog or manually reviewed the original publications. The summary of GWAS datasets is shown in Table <xref rid="tbl1" ref-type="table">1</xref>.</p>
      <table-wrap position="float" id="tbl1">
        <label>Table 1.</label>
        <caption>
          <p>Summary of GWAS datasets</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Source</th>
              <th rowspan="1" colspan="1">Datasets</th>
              <th rowspan="1" colspan="1">URL</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">UK Biobank</td>
              <td rowspan="1" colspan="1">1551</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="http://www.nealelab.is/uk-biobank" ext-link-type="uri">http://www.nealelab.is/uk-biobank</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GWAS Catalog</td>
              <td rowspan="1" colspan="1">340</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://www.ebi.ac.uk/gwas/home" ext-link-type="uri">https://www.ebi.ac.uk/gwas/home</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CARDIoGRAMplusC4D</td>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="http://www.cardiogramplusc4d.org/data-downloads/" ext-link-type="uri">http://www.cardiogramplusc4d.org/data-downloads/</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CDKP/ISGC</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://cd.hugeamp.org/downloads.html" ext-link-type="uri">https://cd.hugeamp.org/downloads.html</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CMDKP</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://hugeamp.org/downloads.html" ext-link-type="uri">https://hugeamp.org/downloads.html</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CVDKP</td>
              <td rowspan="1" colspan="1">3</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://cvd.hugeamp.org/downloads.html" ext-link-type="uri">https://cvd.hugeamp.org/downloads.html</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">RGC</td>
              <td rowspan="1" colspan="1">1</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="http://www.reprogen.org/data_download.html" ext-link-type="uri">http://www.reprogen.org/data_download.html</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">PGC</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://www.med.unc.edu/pgc/results-and-downloads" ext-link-type="uri">https://www.med.unc.edu/pgc/results-and-downloads</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">SDKP</td>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://sleep.hugeamp.org/downloads.html" ext-link-type="uri">https://sleep.hugeamp.org/downloads.html</ext-link>
              </td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T1TFN1">
            <p>CARDIoGRAMplusC4D: Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) Genetics, CDKP/ISGC: Cerebrovascular Disease Knowledge Portal/International Stroke Genetics Consortium, CMDKP: Common Metabolic Diseases Knowledge Portal, CVDKP: Cardiovascular Disease Knowledge Portal, RGC: Reproductive Genetics Consortium, PGC: Psychiatric Genomic Consortium, SDKP: Sleep Disorder Knowledge Portal.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p><italic toggle="yes">Drug perturbation signatures</italic>. The drug-induced gene expression profiles were retrieved from two sources: the Expanded CMap LINCS Resource 2020 (hereafter referred to as CMap2.0) and the SigCom LINCS resource (<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>). For CMap2.0, we downloaded the level 5 data of small molecule compounds along with the metadata including information of compounds, dosage, time, genes and cell lines. SigCom LINCS is a webserver that provides service to process and analyze over a million gene expression signatures. We downloaded the level 5 data from the SigCom LINCS resource (file name: Automatic Human GEO RNA-seq Signatures; access date: 29 May 2023), which included 4269 signatures that could also be used for connectivity analyses.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Data analysis workflow</title>
      <p>We constructed a standard pipeline to infer genetically-informed drugs. First, because gene expression data could be quite tissue-specific, we defined disease-associated genes using the GWAS data and conducted tissue-specific enrichment analysis (TSEA) to identify disease-relevant tissues for TWAS analyses. Second, we applied TWAS in the predicted tissues and obtained the imputed GReX. Third, we conducted connectivity analyses to infer drug candidates by integrating the GWAS-informed signature (GReX) and drug-induced signatures. Finally, we defined candidate disease-drug pairs by combining the results of the six connectivity methods.</p>
      <sec id="SEC2-2-1">
        <title>Tissue-specific enrichment analysis</title>
        <p>We used Multi-marker Analysis of GenoMic Annotation (<italic toggle="yes">MAGMA v1.10</italic>) (<xref rid="B43" ref-type="bibr">43</xref>) to calculate gene-based p-values using GWAS summary statistics. We defined disease-associated genes as those with MAGMA <italic toggle="yes">P</italic> &lt; 0.05 and conducted TSEA by using the <italic toggle="yes">deTS</italic> algorithm to infer disease-relevant tissues (<xref rid="B44" ref-type="bibr">44</xref>). For each GWAS dataset, <italic toggle="yes">deTS</italic> identified the top three tissues that were most relevant to the disease and had <italic toggle="yes">P</italic> &lt; 0.05. We used these tissues for the following analysis.</p>
      </sec>
      <sec id="SEC2-2-2">
        <title>Transcriptome-wide association study</title>
        <p>To impute the GReX signatures in disease-relevant tissues, we used the TWAS method <italic toggle="yes">S-PrediXcan</italic> in this study (<xref rid="B45" ref-type="bibr">45</xref>). We chose Multivariate adaptive shrinkage (Mashr) models trained using the GTEx data (release v8) as the transcriptome prediction models. For each GWAS dataset, we used <italic toggle="yes">S-PrediXcan</italic> to impute GReX in the top 3 disease-relevant tissues as determined by <italic toggle="yes">deTS</italic>. In addition, we imputed GReX in the whole blood tissue for all diseases regardless of their tissue specific context.</p>
      </sec>
      <sec id="SEC2-2-3">
        <title>Connectivity methods and filtering criteria</title>
        <p>We devised and implemented six distinct connectivity methods to infer drug candidates based on several previous benchmark and retrospective studies (<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B46" ref-type="bibr">46–48</xref>). They were the Weighted Connectivity Score (WTCS), Connection Strength Score (CSS), eXtreme Sum score (XSum) and three types of correlation measurements (Spearman, Pearson and Cosine).</p>
        <p>The method WTCS is used in CMap2.0 and employs the Enrichment Score (ES) used in Gene Set Enrichment Analysis (GSEA) (<xref rid="B30" ref-type="bibr">30</xref>). WTCS is defined as follows:</p>
        <disp-formula>
          <tex-math id="M0001" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{eqnarray*}{\mathrm{WTCS}} = {\mathrm{\;}}\left\{ {\begin{array}{@{}*{1}{c}@{}} {\frac{{\left( {E{S_{up}} - E{S_{down}}} \right)}}{2},\;\;if\;sign\left( {E{S_{up}}} \right)\; \ne sign\left( {E{S_{down}}} \right)}\\ {0,\;\;otherwise} \end{array}} \right.\end{eqnarray*}\end{document}</tex-math>
        </disp-formula>
        <p>where <inline-formula><tex-math id="M0001a" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$E{S_{up}}$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M0002" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$E{S_{down}}$\end{document}</tex-math></inline-formula> are the ESs for upregulated and downregulated gene sets, respectively. The sizes of these gene sets are uniformly defined as 50.</p>
        <p>The method CSS measures the strength of the correlation based on the signed ranks of genes in the disease signature and the drug-induced signature. CSS had been shown to perform superior to other methods when evaluated to assess drug–drug similarities using L1000 data (<xref rid="B46" ref-type="bibr">46</xref>). CSS is defined as follows:</p>
        <disp-formula>
          <tex-math id="M0003" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{eqnarray*}{\mathrm{css}}\left( {\vec R,{\mathrm{S}}} \right) = \;\mathop \sum \limits_{i = 1}^{{N_S}} \left[ {r_{drug}^{abs}\left( {g{s_i}} \right) \times sig{n_{drug}}\left( {g{s_i}} \right)} \right]\end{eqnarray*}\end{document}</tex-math>
        </disp-formula>
        <disp-formula>
          <tex-math id="M0004" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{eqnarray*}{\mathrm{cs}}{{\mathrm{s}}_{max}}\left( {{N_{R,}}{N_S}} \right) = \mathop \sum \limits_{i = 1}^{{N_S}} \left( {{N_R} - i + 1} \right)\end{eqnarray*}\end{document}</tex-math>
        </disp-formula>
        <disp-formula>
          <tex-math id="M0005" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{eqnarray*}{\mathrm{CSS}} = \frac{{{\mathrm{css}}\left( {\vec R,{\mathrm{S}}} \right)}}{{{\mathrm{cs}}{{\mathrm{s}}_{max}}\left( {{N_{R,}}{N_S}} \right)}}\end{eqnarray*}\end{document}</tex-math>
        </disp-formula>
        <p>where <inline-formula><tex-math id="M0006" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\vec R$\end{document}</tex-math></inline-formula> is the rank-ordered drug list, <inline-formula><tex-math id="M0007" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${\mathrm{S}}$\end{document}</tex-math></inline-formula> is the unordered disease signature (50 upregulated genes and 50 downregulated genes), <inline-formula><tex-math id="M0008" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${N_S}$\end{document}</tex-math></inline-formula> is the number of genes in <inline-formula><tex-math id="M0009" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${\mathrm{S}}$\end{document}</tex-math></inline-formula> that appears in <inline-formula><tex-math id="M00010" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\vec R$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="M00011" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g{s_i}$\end{document}</tex-math></inline-formula> is the <italic toggle="yes">i</italic>th gene in the set <inline-formula><tex-math id="M00012" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${\mathrm{S}}$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="M00013" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$r_{drug}^{abs}( {g{s_i}} )$\end{document}</tex-math></inline-formula> is the absolute-value-based ranks of <inline-formula><tex-math id="M00014" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g{s_i}$\end{document}</tex-math></inline-formula> in the drug profile, <inline-formula><tex-math id="M00015" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$sig{n_{drug}}( {g{s_i}} )$\end{document}</tex-math></inline-formula> is the sign of <inline-formula><tex-math id="M00016" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g{s_i}$\end{document}</tex-math></inline-formula> in <inline-formula><tex-math id="M00017" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\vec R$\end{document}</tex-math></inline-formula>, and <inline-formula><tex-math id="M00018" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${N_R}$\end{document}</tex-math></inline-formula> is the number of genes in <inline-formula><tex-math id="M00019" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\vec R$\end{document}</tex-math></inline-formula>. To generate the non-parametric <italic toggle="yes">P</italic> value of CSS, we randomly select <inline-formula><tex-math id="M00020" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${N_S}$\end{document}</tex-math></inline-formula> genes in <italic toggle="yes">S</italic> and perform 10 000 permutations.</p>
        <p>The method XSum focuses on top- or bottom-ranked genes and has been shown to perform better than other methods in the inference of drug-indication using the CMap data (<xref rid="B13" ref-type="bibr">13</xref>). The XSum score is defined as follows:</p>
        <disp-quote>
          <p><italic toggle="yes">ChangeByCompound</italic> = top <italic toggle="yes">N</italic> upregulated <inline-formula><tex-math id="M00021" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ \cup$\end{document}</tex-math></inline-formula> top N downregulated genes (compound-treated versus no compound-treated)</p>
          <p><italic toggle="yes">XUpInDisease</italic> = N disease-upregulated genes <inline-formula><tex-math id="M00022" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ \cap$\end{document}</tex-math></inline-formula><italic toggle="yes">ChangeByCompound</italic></p>
          <p><italic toggle="yes">XDownInDisease</italic> = N disease-downregulated genes <inline-formula><tex-math id="M00023" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ \cap$\end{document}</tex-math></inline-formula><italic toggle="yes">ChangeByCompound</italic></p>
          <p><italic toggle="yes">Sum(XUpInDisease)</italic> = sum of Z scores (level 5 data) of compound-induced genes in the set <italic toggle="yes">XUpInDisease</italic></p>
          <p><italic toggle="yes">Sum(XDownInDisease)</italic> = sum of Z scores (level 5 data) of compound-induced genes in the set <italic toggle="yes">XDownInDisease</italic></p>
          <p><italic toggle="yes">XSum</italic> = <italic toggle="yes">Sum(XUpInDisease) - Sum(XDownInDisease)</italic></p>
        </disp-quote>
        <p>Similarly, we calculate the p value of XSum by 10 000 permutations of <italic toggle="yes">XUpInDisease</italic> and <italic toggle="yes">XDownInDisease</italic>. In this study, we set <italic toggle="yes">N</italic> to 50.</p>
        <p>In addition, we calculate three metrics of correlation: Spearman Correlation Coefficient (SCC), Pearson Correlation Coefficient (PCC) and Cosine Correlation Score (CCS) using all shared genes between drug-induced profiles and disease-induced profiles. These three metrics can also be extended to the extremely shared genes between the sets of genes most perturbed (50 upregulated genes + 50 downregulated genes) by the drug and disease (XPearson: eXtreme Pearson correlation; XSpearman: eXtreme Spearman rank correlation; XCosine: eXtreme Cosine correlation).</p>
        <p>With the results of all the six connectivity methods, we define the candidate disease-drug pairs to be included in our database according to the following criteria:</p>
        <p><italic toggle="yes">WTCS &lt; 0 &amp; CSS &lt; 0 &amp; CSS p &lt; 0.05 &amp; XSum &lt; 0 &amp; XSum p &lt; 0.05 &amp; SCC &lt; 0 &amp; PCC &lt; 0 &amp; CCS &lt; 0</italic>.</p>
        <p>Furthermore, to amalgamate the significance derived from all six connectivity methods, we propose a meta-score calculated as the count of methods that identify the correlation with high priority. Specifically, for each dataset-tissue pair, we rank all candidate drugs by their scores from each method. A drug is considered identified with high priority by a method if it is ranked among the top 5% of all candidates by the corresponding method. As a result, each drug receives 6 labels, each indicating whether it is of high priority or not according to each of the six methods. Notably, the range of the meta-score is between 0 and 6 for a total of 6 methods.</p>
      </sec>
    </sec>
    <sec id="SEC2-3">
      <title>Database implementation</title>
      <p>PharmGWAS was deployed in a virtual machine with a CentOS 7.9 environment. Nginx v1.20.1 (<ext-link xlink:href="https://nginx.org/en/" ext-link-type="uri">https://nginx.org/en/</ext-link>) was used as an HTTP and reverse proxy server. We used MySQL (<ext-link xlink:href="https://www.mysql.com" ext-link-type="uri">https://www.mysql.com</ext-link>) as the database engine. The backend RESTful web service was built with Java Spring Boot framework (<ext-link xlink:href="https://spring.io/projects/spring-boot" ext-link-type="uri">https://spring.io/projects/spring-boot</ext-link>). The frontend of the web interface was developed using React (<ext-link xlink:href="https://reactjs.org" ext-link-type="uri">https://reactjs.org</ext-link>) and organized using the UMI (<ext-link xlink:href="https://umijs.org" ext-link-type="uri">https://umijs.org</ext-link>) framework. For the user interface (UI) library, we chose Ant Design (<ext-link xlink:href="https://ant.design" ext-link-type="uri">https://ant.design</ext-link>), which contained a set of high-quality components that could be easily extended to build rich and interactive user interfaces. In addition, the interactive visualization of charts was achieved by using different libraries such as HighCharts (<ext-link xlink:href="https://www.highcharts.com" ext-link-type="uri">https://www.highcharts.com</ext-link>) and ECharts (<ext-link xlink:href="https://echarts.apache.org" ext-link-type="uri">https://echarts.apache.org</ext-link>).</p>
    </sec>
  </sec>
  <sec id="SEC3">
    <title>Database content and usage</title>
    <sec id="SEC3-1">
      <title>Overview of PharmGWAS</title>
      <p>PharmGWAS aims to translate GWAS signals into clinical practice. Currently, PharmGWAS contains 1929 GWAS datasets curated from GWAS Catalog, UKBB and several large consortiums. Moreover, 720216 compound-perturbed gene expression signatures were collected from CMap2.0 and an additional 4269 perturbed signatures were collected from GEO. We implemented our standard pipeline to infer candidate disease-drug pairs for each GWAS dataset. The outline of PharmGWAS is illustrated in Figure <xref rid="F1" ref-type="fig">1</xref>. Currently, PharmGWAS deposits a total of 732947 genetically-informed disease-drug pairs derived from CMap signatures and 7280 pairs from GEO signatures, totaling 740227 (732947 + 7280) disease-drug pairs. Among them, 81.58% (603 874) have a meta-score of 0, 11.40% (84411) have a meta-score of 1, 3.52% (26 021) have 2, 2.89% (21 370) have 3, 0.49% (3652) have 4, 838 have 5, and 61 have 6. In all web pages, the default rule for sorting results is based on the meta-score in descending order. To the best of our knowledge, PharmGWAS is the first systematic and comprehensive database to identify drug repurposing candidates for nearly all available disease traits.</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Schematic overview of PharmGWAS. TSEA: Tissue-Specific Enrichment Analysis. TWAS: Transcriptome Wide Association Studies. GEO: Gene Expression Omnibus. WTCS: Weighted Connectivity Score. CSS: Connection Strength Score. XSum: The eXtreme Sum score.</p>
        </caption>
        <graphic xlink:href="gkad832fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-2">
      <title>Web interface</title>
      <p>PharmGWAS provides a user-friendly interface that allows users to intuitively search, browse and download any results in the database (Figure <xref rid="F2" ref-type="fig">2</xref>). The search function available in the homepage supports keyword-based quick queries for multiple forms of items, such as names of diseases, CMap signatures, or GEO signatures (Figure <xref rid="F2" ref-type="fig">2A</xref>). Meanwhile, users can navigate the entire database through three featured modules: Browse, CMap Results and GEO Results. All processed data in PharmGWAS are freely accessible.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Screenshots of the major web pages for PharmGWAS. (<bold>A</bold>) The homepage search function allows users to quickly query for multiple items including GWAS datasets, CMap signatures and GEO signatures. (<bold>B</bold>) The browse module provides multi-criteria search function to further filter the data of interest. (<bold>C</bold>) Detailed browse page for an individual GWAS dataset. Clicking on the ‘Association ID’ will direct users to view the detailed results and charts for corresponding item and clicking on the ‘CMap Name’ will lead to the PubChem for specific information. (<bold>D</bold>) The detail results page for each candidate disease–drug pair. (<bold>E</bold>) The CMap Results and GEO Results modules.</p>
        </caption>
        <graphic xlink:href="gkad832fig2" position="float"/>
      </fig>
      <p>The Browse module comprises three pages to facilitate exploration of GWAS datasets, CMap signatures and GEO signatures. A series of extended interactive functional modules, such as multi-criteria search and download, are designed to enable users to quickly retrieve relevant data of interest (Figure <xref rid="F2" ref-type="fig">2B</xref>). The Browse page of ‘GWAS datasets’ stores a large amount of key meta information, including data source, disease name, publish year, the sample size of GWAS, the number of cases, the number of controls and so on. The Browse pages of ‘CMap signatures’ and ‘GEO signatures’ also contain a lot of meta information, such as signature name, mechanism of action (MOA), Canonical SMILES, InChiKey, cell line, dose and GEO accession ID and so on. It is worth noting that clicking on the corresponding ‘Dataset Name’ or ‘Signature ID’ button on the row of interest would direct users to a new ‘detail page’ to view detailed results for a specific GWAS dataset or signature. The detail page for a GWAS dataset displays the meta-information about the study, the disease-relevant tissues identified by <italic toggle="yes">deTS</italic> and the drug candidates derived from CMap signatures and GEO signatures (Figure <xref rid="F2" ref-type="fig">2C</xref>). Furthermore, users can filter the results by entering and selecting keywords about the tissue, CMap name, or GEO accession ID. More explanatory information about the column can be viewed by hovering over each entry of table headers and clicking on the header will sort the table by the selected column. By clicking on the ‘CMap Name’ column, users can access the details of the corresponding compound in PubChem (<xref rid="B49" ref-type="bibr">49</xref>), such as chemical and physical properties, clinical trials, consolidated references, patents and so on. By clicking on the ‘Association ID’ column, users will be directed to a dedicated page with detailed results and charts for the item (Figure <xref rid="F2" ref-type="fig">2C</xref>).</p>
      <p>The ‘detail page’ about individual disease-drug pairs contains five sections (Figure <xref rid="F2" ref-type="fig">2D</xref>). First, meta-information about the corresponding disease and drug is shown at the top of the page. Second, we use a radargram to provide an overview of the results from all six connectivity methods. The larger the area enclosed by the results of the six methods, the more reliable the drug candidate is. Third, to assess whether the disease-upregulated genes appear toward the bottom of drug-induced profiles and disease-downregulated genes appear toward the top of drug-induced profiles, the GSEA plots of disease upregulated and downregulated genes in the pre-ranked list of drug signature are provided. Next, the reverse intersection analysis of disease-upregulated genes with drug-downregulated genes is illustrated in Venn diagrams, and similarly for disease-downregulated genes with drug-upregulated genes. Finally, the corresponding Z scores of upregulated and downregulated genes in disease and drug signatures are displayed in the histograms.</p>
      <p>The modules for ‘CMap Results’ and ‘GEO Results’ provide an opportunity to directly search for disease-drug pairs across datasets and signatures (Figure <xref rid="F2" ref-type="fig">2E</xref>). An advanced search function has also been provided. Users can jump to the detail page of disease-drug pairs by clicking on the ‘Association ID’ in the CMap Results and GEO Results pages. In addition, all processed results can be freely downloaded.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Application of PharmGWAS: coronary artery disease as an example</title>
      <p>We take the GWAS dataset of coronary artery disease (CAD) reported by Webb <italic toggle="yes">et al.</italic> (<xref rid="B50" ref-type="bibr">50</xref>) as a case study to demonstrate the application of PharmGWAS (Figure <xref rid="F2" ref-type="fig">2C</xref> and <xref rid="F2" ref-type="fig">D</xref>). CAD is a leading cause of death worldwide with a major heritable component and GWAS has identified ∼60 loci explaining ∼15% of the heritability. The three tissues mostly associated with CAD as determined by using MAGMA and <italic toggle="yes">deTS</italic> were artery coronary (<italic toggle="yes">P</italic> = 0.0070), liver (<italic toggle="yes">P</italic> = 0.0242) and spleen (<italic toggle="yes">P</italic> = 0.0242). We calculated GReX in these three tissues as well as in the whole blood. After connectivity analyses with CMap2.0 signatures, the top-ranked drug candidate was lisofylline (WTCS = −0.5730, XSum = −9.3722, XSum <italic toggle="yes">P</italic> &lt; 1 × 10<sup>−5</sup>, CSS = −0.1464, CSS <italic toggle="yes">P</italic> = 0.0101, SCC = −0.1478, PCC = −0.1996, CCS = −0.1998) in artery coronary (Figure <xref rid="F2" ref-type="fig">2C</xref>). Lisofylline was originally designed as an anti-inflammatory agent and had been investigated for the therapy of diabetes (<xref rid="B51" ref-type="bibr">51</xref>). It had been reported to have suppressive effects on the serum-free fatty acids (<xref rid="B52" ref-type="bibr">52</xref>), a risk factor of atherosclerosis and atherosclerosis was a major complication of diabetes (<xref rid="B53" ref-type="bibr">53</xref>). Besides, pentoxifylline, a methylxanthine derivative of lisofylline, had been proven to have therapeutic benefits on atherosclerosis (<xref rid="B54" ref-type="bibr">54</xref>). Taken together, lisofylline is a reliable candidate drug for the treatment of CAD. These results suggested PharmGWAS could serve as a valuable resource for drug repurposing by leveraging the discovery power of human genetics data.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion and future developments</title>
    <p>In this study, we developed PharmGWAS, a GWAS-based knowledgebase for drug repurposing by incorporating human genetics data and drug perturbation data. To the best of our knowledge, PharmGWAS is the first valuable reference resource that provides the analysis results processed by a unified drug repurposing workflow for thousands of publicly available disease-relevant GWAS datasets. In addition to the wide range of disease types covered by GWAS datasets from multiple sources, the drug perturbation data retrieved from CMap2.0 and the GEO RNA-seq signatures extracted from SigCom LINCS are among the most comprehensive. Our results shed new light on drug discovery, drug combination, drug resistance and drug side effects from the human genetics perspective.</p>
    <p>With the accumulation of new GWAS datasets with increasing amounts of samples, PharmGWAS will be continuously updated by collecting and processing the latest available genetic data. In particular, our results are restricted solely to scientific studies and do not constitute any clinical recommendations. Because of the varying quality of the GWAS datasets and imputed GReX, caution is required in interpreting our results. Moreover, because CMap data are limited to a selection of cell lines rather than tissues, further efforts to expand the repertoire of tissues will enhance the reliability of our results. Lastly, population-scale applications of single-cell sequencing is becoming possible with the development of single-cell sequencing technology and decreasing costs (<xref rid="B55" ref-type="bibr">55–57</xref>). Thus, we anticipate that our framework for drug repurposing based on the TWAS concept will expand at single-cell resolution in the future.</p>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We thank National Genomics Data Center (NGDC) for providing support in database deployment. We are grateful to all members of the Laboratory for Precision Health (LPH) for their valuable comments.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>PharmGWAS is available at <ext-link xlink:href="https://ngdc.cncb.ac.cn/pharmgwas" ext-link-type="uri">https://ngdc.cncb.ac.cn/pharmgwas</ext-link>. Users can freely access all processed data and results through the web service.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>National Natural Science Foundation of China [32270706]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB38010400]; Startup Research Fund of Henan Academy of Sciences [232016009]. Funding for open access charge: National Natural Science Foundation of China [32270706] and Strategic Priority Research Program of Chinese Academy of Sciences [XDB38010400 to P.J.].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Waring</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Arrowsmith</surname><given-names>J.</given-names></string-name>, <string-name><surname>Leach</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Leeson</surname><given-names>P.D.</given-names></string-name>, <string-name><surname>Mandrell</surname><given-names>S.</given-names></string-name>, <string-name><surname>Owen</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Pairaudeau</surname><given-names>G.</given-names></string-name>, <string-name><surname>Pennie</surname><given-names>W.D.</given-names></string-name>, <string-name><surname>Pickett</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>An analysis of the attrition of drug candidates from four major pharmaceutical companies</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2015</year>; <volume>14</volume>:<fpage>475</fpage>–<lpage>486</lpage>.<pub-id pub-id-type="pmid">26091267</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dowden</surname><given-names>H.</given-names></string-name>, <string-name><surname>Munro</surname><given-names>J.</given-names></string-name></person-group><article-title>Trends in clinical success rates and therapeutic focus</article-title>. <source>Nat. Rev. Drug. Discov.</source><year>2019</year>; <volume>18</volume>:<fpage>495</fpage>–<lpage>496</lpage>.<pub-id pub-id-type="pmid">31267067</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pushpakom</surname><given-names>S.</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F.</given-names></string-name>, <string-name><surname>Eyers</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Escott</surname><given-names>K.J.</given-names></string-name>, <string-name><surname>Hopper</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wells</surname><given-names>A.</given-names></string-name>, <string-name><surname>Doig</surname><given-names>A.</given-names></string-name>, <string-name><surname>Guilliams</surname><given-names>T.</given-names></string-name>, <string-name><surname>Latimer</surname><given-names>J.</given-names></string-name>, <string-name><surname>McNamee</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Drug repurposing: progress, challenges and recommendations</article-title>. <source>Nat. Rev. Drug. Discov.</source><year>2019</year>; <volume>18</volume>:<fpage>41</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">30310233</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kunkel</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Suneja</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ebert</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Bongers</surname><given-names>K.S.</given-names></string-name>, <string-name><surname>Fox</surname><given-names>D.K.</given-names></string-name>, <string-name><surname>Malmberg</surname><given-names>S.E.</given-names></string-name>, <string-name><surname>Alipour</surname><given-names>F.</given-names></string-name>, <string-name><surname>Shields</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Adams</surname><given-names>C.M.</given-names></string-name></person-group><article-title>mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass</article-title>. <source>Cell Metab.</source><year>2011</year>; <volume>13</volume>:<fpage>627</fpage>–<lpage>638</lpage>.<pub-id pub-id-type="pmid">21641545</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Ciou</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S.T.</given-names></string-name>, <string-name><surname>Kok</surname><given-names>V.C.</given-names></string-name>, <string-name><surname>Chung</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Tsai</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Kurubanjerdjit</surname><given-names>N.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Ng</surname><given-names>K.L.</given-names></string-name></person-group><article-title>Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular smooth muscle cells</article-title>. <source>PeerJ</source>. <year>2016</year>; <volume>4</volume>:<fpage>e2478</fpage>.<pub-id pub-id-type="pmid">27703845</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Malcomson</surname><given-names>B.</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>H.</given-names></string-name>, <string-name><surname>Veglia</surname><given-names>E.</given-names></string-name>, <string-name><surname>Thillaiyampalam</surname><given-names>G.</given-names></string-name>, <string-name><surname>Barsden</surname><given-names>R.</given-names></string-name>, <string-name><surname>Donegan</surname><given-names>S.</given-names></string-name>, <string-name><surname>El Banna</surname><given-names>A.</given-names></string-name>, <string-name><surname>Elborn</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Ennis</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2016</year>; <volume>113</volume>:<fpage>E3725</fpage>–<lpage>E3734</lpage>.<pub-id pub-id-type="pmid">27286825</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raghavan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Hyter</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pathak</surname><given-names>H.B.</given-names></string-name>, <string-name><surname>Godwin</surname><given-names>A.K.</given-names></string-name>, <string-name><surname>Konecny</surname><given-names>G.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Goode</surname><given-names>E.L.</given-names></string-name>, <string-name><surname>Fridley</surname><given-names>B.L.</given-names></string-name></person-group><article-title>Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer</article-title>. <source>Bmc Genomics [Electronic Resource]</source>. <year>2016</year>; <volume>17</volume>:<fpage>811</fpage>.<pub-id pub-id-type="pmid">27756228</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mirza</surname><given-names>N.</given-names></string-name>, <string-name><surname>Sills</surname><given-names>G.J.</given-names></string-name>, <string-name><surname>Pirmohamed</surname><given-names>M.</given-names></string-name>, <string-name><surname>Marson</surname><given-names>A.G.</given-names></string-name></person-group><article-title>Identifying new antiepileptic drugs through genomics-based drug repurposing</article-title>. <source>Hum. Mol. Genet.</source><year>2017</year>; <volume>26</volume>:<fpage>527</fpage>–<lpage>537</lpage>.<pub-id pub-id-type="pmid">28053048</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Williams</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gatt</surname><given-names>A.</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>E.</given-names></string-name>, <string-name><surname>Corcoran</surname><given-names>J.</given-names></string-name>, <string-name><surname>Doherty</surname><given-names>P.</given-names></string-name>, <string-name><surname>Chambers</surname><given-names>D.</given-names></string-name>, <string-name><surname>Ballard</surname><given-names>C.</given-names></string-name></person-group><article-title>Drug repurposing for Alzheimer's disease based on transcriptional profiling of human iPSC-derived cortical neurons</article-title>. <source>Transl Psychiatry</source>. <year>2019</year>; <volume>9</volume>:<fpage>220</fpage>.<pub-id pub-id-type="pmid">31492831</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Kang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Hao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Bao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Jia</surname><given-names>P.</given-names></string-name></person-group><article-title>CeDR Atlas: a knowledgebase of cellular drug response</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1164</fpage>–<lpage>D1171</lpage>.<pub-id pub-id-type="pmid">34634794</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lamb</surname><given-names>J.</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>E.D.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.</given-names></string-name>, <string-name><surname>Modell</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Blat</surname><given-names>I.C.</given-names></string-name>, <string-name><surname>Wrobel</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Lerner</surname><given-names>J.</given-names></string-name>, <string-name><surname>Brunet</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ross</surname><given-names>K.N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease</article-title>. <source>Science</source>. <year>2006</year>; <volume>313</volume>:<fpage>1929</fpage>–<lpage>1935</lpage>.<pub-id pub-id-type="pmid">17008526</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Gant</surname><given-names>T.W.</given-names></string-name></person-group><article-title>A simple and robust method for connecting small-molecule drugs using gene-expression signatures</article-title>. <source>BMC Bioinf.</source><year>2008</year>; <volume>9</volume>:<fpage>258</fpage>.</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>V.</given-names></string-name>, <string-name><surname>Agarwal</surname><given-names>P.</given-names></string-name></person-group><article-title>Systematic evaluation of connectivity map for disease indications</article-title>. <source>Genome Med.</source><year>2014</year>; <volume>6</volume>:<fpage>540</fpage>.<pub-id pub-id-type="pmid">25606058</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szustakowski</surname><given-names>J.D.</given-names></string-name>, <string-name><surname>Balasubramanian</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kvikstad</surname><given-names>E.</given-names></string-name>, <string-name><surname>Khalid</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bronson</surname><given-names>P.G.</given-names></string-name>, <string-name><surname>Sasson</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>E.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Wade Davis</surname><given-names>J.</given-names></string-name>, <string-name><surname>Haefliger</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank</article-title>. <source>Nat. Genet.</source><year>2021</year>; <volume>53</volume>:<fpage>942</fpage>–<lpage>948</lpage>.<pub-id pub-id-type="pmid">34183854</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reay</surname><given-names>W.R.</given-names></string-name>, <string-name><surname>Cairns</surname><given-names>M.J.</given-names></string-name></person-group><article-title>Advancing the use of genome-wide association studies for drug repurposing</article-title>. <source>Nat. Rev. Genet.</source><year>2021</year>; <volume>22</volume>:<fpage>658</fpage>–<lpage>671</lpage>.<pub-id pub-id-type="pmid">34302145</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carss</surname><given-names>K.J.</given-names></string-name>, <string-name><surname>Deaton</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>Del Rio-Espinola</surname><given-names>A.</given-names></string-name>, <string-name><surname>Diogo</surname><given-names>D.</given-names></string-name>, <string-name><surname>Fielden</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kulkarni</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Moggs</surname><given-names>J.</given-names></string-name>, <string-name><surname>Newham</surname><given-names>P.</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Sistare</surname><given-names>F.D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Using human genetics to improve safety assessment of therapeutics</article-title>. <source>Nat. Rev. Drug. Discov.</source><year>2023</year>; <volume>22</volume>:<fpage>145</fpage>–<lpage>162</lpage>.<pub-id pub-id-type="pmid">36261593</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ochoa</surname><given-names>D.</given-names></string-name>, <string-name><surname>Karim</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ghoussaini</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hulcoop</surname><given-names>D.G.</given-names></string-name>, <string-name><surname>McDonagh</surname><given-names>E.M.</given-names></string-name>, <string-name><surname>Dunham</surname><given-names>I.</given-names></string-name></person-group><article-title>Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs</article-title>. <source>Nat. Rev. Drug. Discov.</source><year>2022</year>; <volume>21</volume>:<fpage>551</fpage>.<pub-id pub-id-type="pmid">35804044</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nelson</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Tipney</surname><given-names>H.</given-names></string-name>, <string-name><surname>Painter</surname><given-names>J.L.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Nicoletti</surname><given-names>P.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Floratos</surname><given-names>A.</given-names></string-name>, <string-name><surname>Sham</surname><given-names>P.C.</given-names></string-name>, <string-name><surname>Li</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The support of human genetic evidence for approved drug indications</article-title>. <source>Nat. Genet.</source><year>2015</year>; <volume>47</volume>:<fpage>856</fpage>–<lpage>860</lpage>.<pub-id pub-id-type="pmid">26121088</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Okada</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Trynka</surname><given-names>G.</given-names></string-name>, <string-name><surname>Raj</surname><given-names>T.</given-names></string-name>, <string-name><surname>Terao</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ikari</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kochi</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ohmura</surname><given-names>K.</given-names></string-name>, <string-name><surname>Suzuki</surname><given-names>A.</given-names></string-name>, <string-name><surname>Yoshida</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genetics of rheumatoid arthritis contributes to biology and drug discovery</article-title>. <source>Nature</source>. <year>2014</year>; <volume>506</volume>:<fpage>376</fpage>–<lpage>381</lpage>.<pub-id pub-id-type="pmid">24390342</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Plenge</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Scolnick</surname><given-names>E.M.</given-names></string-name>, <string-name><surname>Altshuler</surname><given-names>D</given-names></string-name></person-group><article-title>Validating therapeutic targets through human genetics</article-title>. <source>Nat. Rev. Drug. Discov.</source><year>2013</year>; <volume>12</volume>:<fpage>581</fpage>–<lpage>594</lpage>.<pub-id pub-id-type="pmid">23868113</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Duerr</surname><given-names>R.H.</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>K.D.</given-names></string-name>, <string-name><surname>Brant</surname><given-names>S.R.</given-names></string-name>, <string-name><surname>Rioux</surname><given-names>J.D.</given-names></string-name>, <string-name><surname>Silverberg</surname><given-names>M.S.</given-names></string-name>, <string-name><surname>Daly</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Steinhart</surname><given-names>A.H.</given-names></string-name>, <string-name><surname>Abraham</surname><given-names>C.</given-names></string-name>, <string-name><surname>Regueiro</surname><given-names>M.</given-names></string-name>, <string-name><surname>Griffiths</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A genome-wide association study identifies IL23R as an inflammatory bowel disease gene</article-title>. <source>Science</source>. <year>2006</year>; <volume>314</volume>:<fpage>1461</fpage>–<lpage>1463</lpage>.<pub-id pub-id-type="pmid">17068223</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feagan</surname><given-names>B.G.</given-names></string-name>, <string-name><surname>Sandborn</surname><given-names>W.J.</given-names></string-name>, <string-name><surname>Gasink</surname><given-names>C.</given-names></string-name>, <string-name><surname>Jacobstein</surname><given-names>D.</given-names></string-name>, <string-name><surname>Lang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Friedman</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Blank</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Johanns</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>L.L.</given-names></string-name>, <string-name><surname>Miao</surname><given-names>Y.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease</article-title>. <source>N. Engl. J. Med.</source><year>2016</year>; <volume>375</volume>:<fpage>1946</fpage>–<lpage>1960</lpage>.<pub-id pub-id-type="pmid">27959607</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Wacholder</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gail</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Peters</surname><given-names>U.</given-names></string-name>, <string-name><surname>Jacobs</surname><given-names>K.B.</given-names></string-name>, <string-name><surname>Chanock</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Chatterjee</surname><given-names>N.</given-names></string-name></person-group><article-title>Estimation of effect size distribution from genome-wide association studies and implications for future discoveries</article-title>. <source>Nat. Genet.</source><year>2010</year>; <volume>42</volume>:<fpage>570</fpage>–<lpage>575</lpage>.<pub-id pub-id-type="pmid">20562874</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>UCLEB Consortium</collab><string-name><surname>Speed</surname><given-names>D.</given-names></string-name>, <string-name><surname>Cai</surname><given-names>N.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Nejentsev</surname><given-names>S.</given-names></string-name>, <string-name><surname>Balding</surname><given-names>D.J.</given-names></string-name></person-group><article-title>Reevaluation of SNP heritability in complex human traits</article-title>. <source>Nat. Genet.</source><year>2017</year>; <volume>49</volume>:<fpage>986</fpage>–<lpage>992</lpage>.<pub-id pub-id-type="pmid">28530675</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Goddard</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Wray</surname><given-names>N.R.</given-names></string-name>, <string-name><surname>Visscher</surname><given-names>P.M.</given-names></string-name></person-group><article-title>Concepts, estimation and interpretation of SNP-based heritability</article-title>. <source>Nat. Genet.</source><year>2017</year>; <volume>49</volume>:<fpage>1304</fpage>–<lpage>1310</lpage>.<pub-id pub-id-type="pmid">28854176</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khera</surname><given-names>A.V.</given-names></string-name>, <string-name><surname>Chaffin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Aragam</surname><given-names>K.G.</given-names></string-name>, <string-name><surname>Haas</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Roselli</surname><given-names>C.</given-names></string-name>, <string-name><surname>Choi</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Natarajan</surname><given-names>P.</given-names></string-name>, <string-name><surname>Lander</surname><given-names>E.S.</given-names></string-name>, <string-name><surname>Lubitz</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Ellinor</surname><given-names>P.T.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations</article-title>. <source>Nat. Genet.</source><year>2018</year>; <volume>50</volume>:<fpage>1219</fpage>–<lpage>1224</lpage>.<pub-id pub-id-type="pmid">30104762</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>So</surname><given-names>H.C.</given-names></string-name>, <string-name><surname>Chau</surname><given-names>C.K.</given-names></string-name>, <string-name><surname>Chiu</surname><given-names>W.T.</given-names></string-name>, <string-name><surname>Ho</surname><given-names>K.S.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>C.P.</given-names></string-name>, <string-name><surname>Yim</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Sham</surname><given-names>P.C.</given-names></string-name></person-group><article-title>Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry</article-title>. <source>Nat. Neurosci.</source><year>2017</year>; <volume>20</volume>:<fpage>1342</fpage>–<lpage>1349</lpage>.<pub-id pub-id-type="pmid">28805813</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Woodward</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Thorp</surname><given-names>J.G.</given-names></string-name>, <string-name><surname>Akosile</surname><given-names>W.</given-names></string-name>, <string-name><surname>Ong</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Gamazon</surname><given-names>E.R.</given-names></string-name>, <string-name><surname>Derks</surname><given-names>E.M.</given-names></string-name>, <string-name><surname>Gerring</surname><given-names>Z.F.</given-names></string-name></person-group><article-title>Identification of drug repurposing candidates for the treatment of anxiety: a genetic approach</article-title>. <source>Psychiatry Res.</source><year>2023</year>; <volume>326</volume>:<fpage>115343</fpage>.<pub-id pub-id-type="pmid">37473490</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>P.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Kerchberger</surname><given-names>V.E.</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>B.</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>T.L.</given-names></string-name>, <string-name><surname>Cox</surname><given-names>N.J.</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Stein</surname><given-names>C.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension</article-title>. <source>Nat. Commun.</source><year>2022</year>; <volume>13</volume>:<fpage>46</fpage>.<pub-id pub-id-type="pmid">35013250</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.D.</given-names></string-name>, <string-name><surname>Natoli</surname><given-names>T.E.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Gould</surname><given-names>J.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Tubelli</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Asiedu</surname><given-names>J.K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles</article-title>. <source>Cell</source>. <year>2017</year>; <volume>171</volume>:<fpage>1437</fpage>–<lpage>1452</lpage>.<pub-id pub-id-type="pmid">29195078</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Evangelista</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>D.J.B.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Lachmann</surname><given-names>A.</given-names></string-name>, <string-name><surname>Jeon</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>K.</given-names></string-name>, <string-name><surname>Jagodnik</surname><given-names>K.M.</given-names></string-name>, <string-name><surname>Jenkins</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Kuleshov</surname><given-names>M.V.</given-names></string-name>, <string-name><surname>Wojciechowicz</surname><given-names>M.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>SigCom LINCS: data and metadata search engine for a million gene expression signatures</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>W697</fpage>–<lpage>W709</lpage>.<pub-id pub-id-type="pmid">35524556</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sollis</surname><given-names>E.</given-names></string-name>, <string-name><surname>Mosaku</surname><given-names>A.</given-names></string-name>, <string-name><surname>Abid</surname><given-names>A.</given-names></string-name>, <string-name><surname>Buniello</surname><given-names>A.</given-names></string-name>, <string-name><surname>Cerezo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Gil</surname><given-names>L.</given-names></string-name>, <string-name><surname>Groza</surname><given-names>T.</given-names></string-name>, <string-name><surname>Gunes</surname><given-names>O.</given-names></string-name>, <string-name><surname>Hall</surname><given-names>P.</given-names></string-name>, <string-name><surname>Hayhurst</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D977</fpage>–<lpage>D985</lpage>.<pub-id pub-id-type="pmid">36350656</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sudlow</surname><given-names>C.</given-names></string-name>, <string-name><surname>Gallacher</surname><given-names>J.</given-names></string-name>, <string-name><surname>Allen</surname><given-names>N.</given-names></string-name>, <string-name><surname>Beral</surname><given-names>V.</given-names></string-name>, <string-name><surname>Burton</surname><given-names>P.</given-names></string-name>, <string-name><surname>Danesh</surname><given-names>J.</given-names></string-name>, <string-name><surname>Downey</surname><given-names>P.</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>P.</given-names></string-name>, <string-name><surname>Green</surname><given-names>J.</given-names></string-name>, <string-name><surname>Landray</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age</article-title>. <source>PLoS Med.</source><year>2015</year>; <volume>12</volume>:<fpage>e1001779</fpage>.<pub-id pub-id-type="pmid">25826379</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nelson</surname><given-names>C.P.</given-names></string-name>, <string-name><surname>Goel</surname><given-names>A.</given-names></string-name>, <string-name><surname>Butterworth</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Kanoni</surname><given-names>S.</given-names></string-name>, <string-name><surname>Webb</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Marouli</surname><given-names>E.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ntalla</surname><given-names>I.</given-names></string-name>, <string-name><surname>Lai</surname><given-names>F.Y.</given-names></string-name>, <string-name><surname>Hopewell</surname><given-names>J.C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Association analyses based on false discovery rate implicate new loci for coronary artery disease</article-title>. <source>Nat. Genet.</source><year>2017</year>; <volume>49</volume>:<fpage>1385</fpage>–<lpage>1391</lpage>.<pub-id pub-id-type="pmid">28714975</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Traylor</surname><given-names>M.</given-names></string-name>, <string-name><surname>Malik</surname><given-names>R.</given-names></string-name>, <string-name><surname>Nalls</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Cotlarciuc</surname><given-names>I.</given-names></string-name>, <string-name><surname>Radmanesh</surname><given-names>F.</given-names></string-name>, <string-name><surname>Thorleifsson</surname><given-names>G.</given-names></string-name>, <string-name><surname>Hanscombe</surname><given-names>K.B.</given-names></string-name>, <string-name><surname>Langefeld</surname><given-names>C.</given-names></string-name>, <string-name><surname>Saleheen</surname><given-names>D.</given-names></string-name>, <string-name><surname>Rost</surname><given-names>N.S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genetic variation at 16q24.2 is associated with small vessel stroke</article-title>. <source>Ann. Neurol.</source><year>2017</year>; <volume>81</volume>:<fpage>383</fpage>–<lpage>394</lpage>.<pub-id pub-id-type="pmid">27997041</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sandholm</surname><given-names>N.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Nair</surname><given-names>V.</given-names></string-name>, <string-name><surname>Sheng</surname><given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ahlqvist</surname><given-names>E.</given-names></string-name>, <string-name><surname>van Zuydam</surname><given-names>N.</given-names></string-name>, <string-name><surname>Dahlstrom</surname><given-names>E.H.</given-names></string-name>, <string-name><surname>Fermin</surname><given-names>D.</given-names></string-name>, <string-name><surname>Smyth</surname><given-names>L.J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease</article-title>. <source>Diabetologia</source>. <year>2022</year>; <volume>65</volume>:<fpage>1495</fpage>–<lpage>1509</lpage>.<pub-id pub-id-type="pmid">35763030</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roselli</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Nauffal</surname><given-names>V.</given-names></string-name>, <string-name><surname>Georges</surname><given-names>A.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Love</surname><given-names>K.</given-names></string-name>, <string-name><surname>Weng</surname><given-names>L.C.</given-names></string-name>, <string-name><surname>Delling</surname><given-names>F.N.</given-names></string-name>, <string-name><surname>Maurya</surname><given-names>S.R.</given-names></string-name>, <string-name><surname>Schrolkamp</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse</article-title>. <source>Eur. Heart J.</source><year>2022</year>; <volume>43</volume>:<fpage>1668</fpage>–<lpage>1680</lpage>.<pub-id pub-id-type="pmid">35245370</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nauffal</surname><given-names>V.</given-names></string-name>, <string-name><surname>Di Achille</surname><given-names>P.</given-names></string-name>, <string-name><surname>Klarqvist</surname><given-names>M.D.R.</given-names></string-name>, <string-name><surname>Cunningham</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Hill</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Pirruccello</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Weng</surname><given-names>L.C.</given-names></string-name>, <string-name><surname>Morrill</surname><given-names>V.N.</given-names></string-name>, <string-name><surname>Choi</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Khurshid</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genetics of myocardial interstitial fibrosis in the human heart and association with disease</article-title>. <source>Nat. Genet.</source><year>2023</year>; <volume>55</volume>:<fpage>777</fpage>–<lpage>786</lpage>.<pub-id pub-id-type="pmid">37081215</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ruth</surname><given-names>K.S.</given-names></string-name>, <string-name><surname>Day</surname><given-names>F.R.</given-names></string-name>, <string-name><surname>Hussain</surname><given-names>J.</given-names></string-name>, <string-name><surname>Martinez-Marchal</surname><given-names>A.</given-names></string-name>, <string-name><surname>Aiken</surname><given-names>C.E.</given-names></string-name>, <string-name><surname>Azad</surname><given-names>A.</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Knoblochova</surname><given-names>L.</given-names></string-name>, <string-name><surname>Abe</surname><given-names>H.</given-names></string-name>, <string-name><surname>Tarry-Adkins</surname><given-names>J.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genetic insights into biological mechanisms governing human ovarian ageing</article-title>. <source>Nature</source>. <year>2021</year>; <volume>596</volume>:<fpage>393</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">34349265</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mullins</surname><given-names>N.</given-names></string-name>, <string-name><surname>Forstner</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>O’Connell</surname><given-names>K.S.</given-names></string-name>, <string-name><surname>Coombes</surname><given-names>B.</given-names></string-name>, <string-name><surname>Coleman</surname><given-names>J.R.I.</given-names></string-name>, <string-name><surname>Qiao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Als</surname><given-names>T.D.</given-names></string-name>, <string-name><surname>Bigdeli</surname><given-names>T.B.</given-names></string-name>, <string-name><surname>Borte</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bryois</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology</article-title>. <source>Nat. Genet.</source><year>2021</year>; <volume>53</volume>:<fpage>817</fpage>–<lpage>829</lpage>.<pub-id pub-id-type="pmid">34002096</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cade</surname><given-names>B.E.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.</given-names></string-name>, <string-name><surname>Sofer</surname><given-names>T.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Gharib</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Gottlieb</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>X.</given-names></string-name>, <string-name><surname>Lane</surname><given-names>J.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Whole-genome association analyses of sleep-disordered breathing phenotypes in the NHLBI TOPMed program</article-title>. <source>Genome Med.</source><year>2021</year>; <volume>13</volume>:<fpage>136</fpage>.<pub-id pub-id-type="pmid">34446064</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><collab>GTEx Consortium</collab><article-title>The GTEx Consortium atlas of genetic regulatory effects across human tissues</article-title>. <source>Science</source>. <year>2020</year>; <volume>369</volume>:<fpage>1318</fpage>–<lpage>1330</lpage>.<pub-id pub-id-type="pmid">32913098</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Leeuw</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Mooij</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Heskes</surname><given-names>T.</given-names></string-name>, <string-name><surname>Posthuma</surname><given-names>D</given-names></string-name></person-group><article-title>MAGMA: generalized gene-set analysis of GWAS data</article-title>. <source>PLoS Comput. Biol.</source><year>2015</year>; <volume>11</volume>:<fpage>e1004219</fpage>.<pub-id pub-id-type="pmid">25885710</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pei</surname><given-names>G.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Jia</surname><given-names>P.</given-names></string-name></person-group><article-title>deTS: tissue-specific enrichment analysis to decode tissue specificity</article-title>. <source>Bioinformatics</source>. <year>2019</year>; <volume>35</volume>:<fpage>3842</fpage>–<lpage>3845</lpage>.<pub-id pub-id-type="pmid">30824912</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barbeira</surname><given-names>A.N.</given-names></string-name>, <string-name><surname>Dickinson</surname><given-names>S.P.</given-names></string-name>, <string-name><surname>Bonazzola</surname><given-names>R.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wheeler</surname><given-names>H.E.</given-names></string-name>, <string-name><surname>Torres</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Torstenson</surname><given-names>E.S.</given-names></string-name>, <string-name><surname>Shah</surname><given-names>K.P.</given-names></string-name>, <string-name><surname>Garcia</surname><given-names>T.</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>T.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics</article-title>. <source>Nat. Commun.</source><year>2018</year>; <volume>9</volume>:<fpage>1825</fpage>.<pub-id pub-id-type="pmid">29739930</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname><given-names>K.</given-names></string-name>, <string-name><surname>Li</surname><given-names>L.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Teng</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Z.J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>D.</given-names></string-name></person-group><article-title>A comprehensive evaluation of connectivity methods for L1000 data</article-title>. <source>Brief Bioinform</source>. <year>2020</year>; <volume>21</volume>:<fpage>2194</fpage>–<lpage>2205</lpage>.<pub-id pub-id-type="pmid">31774912</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Struckmann</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ernst</surname><given-names>M.</given-names></string-name>, <string-name><surname>Fischer</surname><given-names>S.</given-names></string-name>, <string-name><surname>Mah</surname><given-names>N.</given-names></string-name>, <string-name><surname>Fuellen</surname><given-names>G.</given-names></string-name>, <string-name><surname>Moller</surname><given-names>S.</given-names></string-name></person-group><article-title>Scoring functions for drug-effect similarity</article-title>. <source>Brief Bioinform</source>. <year>2021</year>; <volume>22</volume>:<fpage>1</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">33401308</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Samart</surname><given-names>K.</given-names></string-name>, <string-name><surname>Tuyishime</surname><given-names>P.</given-names></string-name>, <string-name><surname>Krishnan</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ravi</surname><given-names>J.</given-names></string-name></person-group><article-title>Reconciling multiple connectivity scores for drug repurposing</article-title>. <source>Brief Bioinform</source>. <year>2021</year>; <volume>22</volume>:<fpage>1</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">33401308</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>T.</given-names></string-name>, <string-name><surname>Gindulyte</surname><given-names>A.</given-names></string-name>, <string-name><surname>He</surname><given-names>J.</given-names></string-name>, <string-name><surname>He</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Shoemaker</surname><given-names>B.A.</given-names></string-name>, <string-name><surname>Thiessen</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>PubChem 2023 update</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D1373</fpage>–<lpage>D1380</lpage>.<pub-id pub-id-type="pmid">36305812</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Webb</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Erdmann</surname><given-names>J.</given-names></string-name>, <string-name><surname>Stirrups</surname><given-names>K.E.</given-names></string-name>, <string-name><surname>Stitziel</surname><given-names>N.O.</given-names></string-name>, <string-name><surname>Masca</surname><given-names>N.G.</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kanoni</surname><given-names>S.</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>C.P.</given-names></string-name>, <string-name><surname>Ferrario</surname><given-names>P.G.</given-names></string-name>, <string-name><surname>Konig</surname><given-names>I.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Systematic evaluation of pleiotropy identifies 6 further loci associated with coronary artery disease</article-title>. <source>J. Am. Coll. Cardiol.</source><year>2017</year>; <volume>69</volume>:<fpage>823</fpage>–<lpage>836</lpage>.<pub-id pub-id-type="pmid">28209224</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>Z.D.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>R.</given-names></string-name>, <string-name><surname>McDuffie</surname><given-names>M.</given-names></string-name>, <string-name><surname>Nadler</surname><given-names>J.L.</given-names></string-name></person-group><article-title>The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice</article-title>. <source>Diabetologia</source>. <year>2002</year>; <volume>45</volume>:<fpage>1307</fpage>–<lpage>1314</lpage>.<pub-id pub-id-type="pmid">12242464</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bursten</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Federighi</surname><given-names>D.</given-names></string-name>, <string-name><surname>Wald</surname><given-names>J.</given-names></string-name>, <string-name><surname>Meengs</surname><given-names>B.</given-names></string-name>, <string-name><surname>Spickler</surname><given-names>W.</given-names></string-name>, <string-name><surname>Nudelman</surname><given-names>E.</given-names></string-name></person-group><article-title>Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids</article-title>. <source>J. Pharmacol. Exp. Ther.</source><year>1998</year>; <volume>284</volume>:<fpage>337</fpage>–<lpage>345</lpage>.<pub-id pub-id-type="pmid">9435196</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beckman</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Creager</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Libby</surname><given-names>P.</given-names></string-name></person-group><article-title>Diabetes and atherosclerosis: epidemiology, pathophysiology, and management</article-title>. <source>JAMA</source>. <year>2002</year>; <volume>287</volume>:<fpage>2570</fpage>–<lpage>2581</lpage>.<pub-id pub-id-type="pmid">12020339</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Laurat</surname><given-names>E.</given-names></string-name>, <string-name><surname>Poirier</surname><given-names>B.</given-names></string-name>, <string-name><surname>Tupin</surname><given-names>E.</given-names></string-name>, <string-name><surname>Caligiuri</surname><given-names>G.</given-names></string-name>, <string-name><surname>Hansson</surname><given-names>G.K.</given-names></string-name>, <string-name><surname>Bariety</surname><given-names>J.</given-names></string-name>, <string-name><surname>Nicoletti</surname><given-names>A.</given-names></string-name></person-group><article-title>In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice</article-title>. <source>Circulation</source>. <year>2001</year>; <volume>104</volume>:<fpage>197</fpage>–<lpage>202</lpage>.<pub-id pub-id-type="pmid">11447086</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sumida</surname><given-names>T.S.</given-names></string-name>, <string-name><surname>Hafler</surname><given-names>D.A.</given-names></string-name></person-group><article-title>Population genetics meets single-cell sequencing</article-title>. <source>Science</source>. <year>2022</year>; <volume>376</volume>:<fpage>134</fpage>–<lpage>135</lpage>.<pub-id pub-id-type="pmid">35389792</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yazar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Alquicira-Hernandez</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wing</surname><given-names>K.</given-names></string-name>, <string-name><surname>Senabouth</surname><given-names>A.</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>M.G.</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Rowson</surname><given-names>A.</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>T.R.P.</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease</article-title>. <source>Science</source>. <year>2022</year>; <volume>376</volume>:<fpage>eabf3041</fpage>.<pub-id pub-id-type="pmid">35389779</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perez</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>M.G.</given-names></string-name>, <string-name><surname>Subramaniam</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kim</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Hartoularos</surname><given-names>G.C.</given-names></string-name>, <string-name><surname>Targ</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ogorodnikov</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bueno</surname><given-names>R.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus</article-title>. <source>Science</source>. <year>2022</year>; <volume>376</volume>:<fpage>eabf1970</fpage>.<pub-id pub-id-type="pmid">35389781</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10767932</article-id>
    <article-id pub-id-type="pmid">37831083</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad832</article-id>
    <article-id pub-id-type="publisher-id">gkad832</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>PharmGWAS: a GWAS-based knowledgebase for drug repurposing</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9581-1329</contrib-id>
        <name>
          <surname>Kang</surname>
          <given-names>Hongen</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing</addr-line> 100049, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Pan</surname>
          <given-names>Siyu</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing</addr-line> 100049, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lin</surname>
          <given-names>Shiqi</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing</addr-line> 100049, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Yin-Ying</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3614-2441</contrib-id>
        <name>
          <surname>Yuan</surname>
          <given-names>Na</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4523-4153</contrib-id>
        <name>
          <surname>Jia</surname>
          <given-names>Peilin</given-names>
        </name>
        <!--pjia@big.ac.cn-->
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing</addr-line> 100049, <country country="CN">China</country></aff>
        <aff><institution>National Genomics Data Center, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing</addr-line> 100101, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 10 84097798; Email: <email>pjia@big.ac.cn</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-10-13">
      <day>13</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>13</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <volume>52</volume>
    <issue>D1</issue>
    <fpage>D972</fpage>
    <lpage>D979</lpage>
    <history>
      <date date-type="accepted">
        <day>21</day>
        <month>9</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>9</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>14</day>
        <month>8</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad832.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Leveraging genetics insights to promote drug repurposing has become a promising and active strategy in pharmacology. Indeed, among the 50 drugs approved by FDA in 2021, two-thirds have genetically supported evidence. In this regard, the increasing amount of widely available genome-wide association studies (GWAS) datasets have provided substantial opportunities for drug repurposing based on genetics discoveries. Here, we developed PharmGWAS, a comprehensive knowledgebase designed to identify candidate drugs through the integration of GWAS data. PharmGWAS focuses on novel connections between diseases and small-molecule compounds derived using a reverse relationship between the genetically-regulated expression signature and the drug-induced signature. Specifically, we collected and processed 1929 GWAS datasets across a diverse spectrum of diseases and 724 485 perturbation signatures pertaining to a substantial 33609 molecular compounds. To obtain reliable and robust predictions for the reverse connections, we implemented six distinct connectivity methods. In the current version, PharmGWAS deposits a total of 740 227 genetically-informed disease-drug pairs derived from drug-perturbation signatures, presenting a valuable and comprehensive catalog. Further equipped with its user-friendly web design, PharmGWAS is expected to greatly aid the discovery of novel drugs, the exploration of drug combination therapies and the identification of drug resistance or side effects. PharmGWAS is available at <ext-link xlink:href="https://ngdc.cncb.ac.cn/pharmgwas" ext-link-type="uri">https://ngdc.cncb.ac.cn/pharmgwas</ext-link>.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkad832figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32270706</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Strategic Priority Research Program of the Chinese Academy of Sciences</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Startup Research Fund of Henan Academy of Sciences</institution>
          </institution-wrap>
        </funding-source>
        <award-id>232016009</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="8"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>The development of novel drugs is a daunting and time- and cost-consuming process, which severely impedes the translation of scientific breakthroughs into clinical applications (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>). To address this challenge, drug repurposing, also known as drug repositioning, has emerged as a promising strategy. Drug repurposing seeks to identify novel clinical applications for existing medications or drugs, offering accelerated timelines, reduced risks and lower expenses compared to the traditional de novo drug discovery pipeline.</p>
    <p>Diverse computational approaches have been developed to aid the identification of repurposing candidates, such as signature matching, molecular docking and retrospective clinical analysis and so on (<xref rid="B3" ref-type="bibr">3</xref>). Among these, the signature matching approach, also called the connectivity approach, has been proven particularly effective in discovering new drug repurposing candidates across a wide spectrum of therapeutic domains, even at the level of single-cell resolution (<xref rid="B4" ref-type="bibr">4–10</xref>). It usually involves the comparison of the signature of a drug, often derived through differential gene expression analysis before and after drug treatment, with that of another disease phenotype. The degree of inverse correlation between the two signatures can provide insights into whether the drug may revert the disease phenotype itself. Specifically, representative signature-based methods, or connectivity methods, included the Connectivity Score, which was based on Kolmogorov-Smirnov (KS) statistics and was first implemented by the Connectivity Map (CMap) project (<xref rid="B11" ref-type="bibr">11</xref>). Later, other methods were reported not only measuring the strength of the inverse connections but also assessing the statistical significance of the connections (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>), such as the Connection Strength Score (CSS) and eXtreme sum (XSum) score.</p>
    <p>Recently, advances in genome-wide association studies (GWAS) have revealed important biological insights into complex diseases. These genetics discoveries can assist in identifying compounds suitable for tailored treatments to the respective diseases (<xref rid="B14" ref-type="bibr">14–16</xref>). Indeed, among the 50 drugs approved by FDA in 2021, two-thirds have genetically supported evidence (<xref rid="B17" ref-type="bibr">17</xref>). Traditionally, GWAS signals may provide opportunities for selecting candidate drug targets by identifying the causal variants and genes with large effect sizes (<xref rid="B18" ref-type="bibr">18–20</xref>). For example, IL23R was identified by GWAS as a repurposing candidate for Crohn's disease (<xref rid="B21" ref-type="bibr">21</xref>), and the corresponding drug, ustekinumab, had been shown to have a significant therapeutic effect on IL23R (<xref rid="B22" ref-type="bibr">22</xref>). However, the majority of significant variants are located in the non-coding regions of the genome, making it quite challenging to identify the causal genes. Furthermore, the majority of common variants identified in GWAS had small to modest individual effects on traits, which may not be substantial enough for therapeutic intervention. On the contrary, the combined polygenic effect of many such variants could be considerably large and constitute a significant portion of the overall trait heritability (<xref rid="B23" ref-type="bibr">23–26</xref>). To leverage the discovery power of the vast majority of common variants, GWAS summary statistics can be used to impute the genetically regulated expression (GReX) profile and then compare with the drug-induced gene expression profiles, such as those generated by the Connectivity Map project (<xref rid="B11" ref-type="bibr">11</xref>). Such extended signature matching strategies had been successfully applied in psychiatric disorders (<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>), blood traits (<xref rid="B29" ref-type="bibr">29</xref>) among others. However, there is still a lack of a systematic and comprehensive knowledgebase for genetically-informed drug repurposing for a wide range of complex diseases.</p>
    <p>To address this issue, we developed PharmGWAS, a knowledgebase for GWAS-informed drug repurposing across a diverse spectrum of diseases. We constructed a standard computational inference workflow to first implement the transcriptome-wide association study (TWAS) strategy and impute the GReX signatures in disease-relevant tissues for each GWAS dataset. We also curated a comprehensive list of drug-induced gene expression profiles from the CMap project and the Gene Expression Omnibus (GEO) database (<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>). We then implemented six computational methods to search for the drug-induced signatures that had a negative correlation with the GReX signature. These methods have been well-reported and evaluated in literature to successfully connect diseases and candidate drugs. PharmGWAS thus provides a valuable reference resource by leveraging genetic evidence to aid the discovery of novel drugs, the exploration of drug combination therapies and the identification of drug resistance or side effects.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Data collection</title>
      <p><italic toggle="yes">GWAS summary statistics</italic>. We downloaded GWAS summary statistics mainly from three sources: GWAS Catalog (<xref rid="B32" ref-type="bibr">32</xref>), UK BioBank (UKBB) (<xref rid="B33" ref-type="bibr">33</xref>) and large consortiums dedicated to diverse diseases, including Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) Genetics Consortium (<xref rid="B34" ref-type="bibr">34</xref>), Cerebrovascular Disease Knowledge Portal/International Stroke Genetics Consortium (CDKP/ISGC) (<xref rid="B35" ref-type="bibr">35</xref>), Common Metabolic Diseases Knowledge Portal (CMDKP) (<xref rid="B36" ref-type="bibr">36</xref>), Cardiovascular Disease Knowledge Portal (CVDKP) (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>), Reproductive Genetics Consortium (RGC) (<xref rid="B39" ref-type="bibr">39</xref>), Psychiatric Genomic Consortium (PGC) (<xref rid="B40" ref-type="bibr">40</xref>) and Sleep Disorder Knowledge Portal (SDKP) (<xref rid="B41" ref-type="bibr">41</xref>). According to the Experimental Factor Ontology (EFO) provided by GWAS Catalog, we filtered out the GWAS data where the trait description did not map to the disease terms in the EFO. Also, we only retained disease-related GWAS data for UKBB according to the international classification of diseases (ICD-10), cancer code and non-cancer illness code. Considering that the TWAS prediction models were built based on reference data of European ancestry (<xref rid="B42" ref-type="bibr">42</xref>), we only kept the GWAS data from European ancestry in our current version of PharmGWAS. Redundant datasets were removed. We also collected metadata such as sample size, ancestry and release year of the datasets from GWAS Catalog or manually reviewed the original publications. The summary of GWAS datasets is shown in Table <xref rid="tbl1" ref-type="table">1</xref>.</p>
      <table-wrap position="float" id="tbl1">
        <label>Table 1.</label>
        <caption>
          <p>Summary of GWAS datasets</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Source</th>
              <th rowspan="1" colspan="1">Datasets</th>
              <th rowspan="1" colspan="1">URL</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">UK Biobank</td>
              <td rowspan="1" colspan="1">1551</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="http://www.nealelab.is/uk-biobank" ext-link-type="uri">http://www.nealelab.is/uk-biobank</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GWAS Catalog</td>
              <td rowspan="1" colspan="1">340</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://www.ebi.ac.uk/gwas/home" ext-link-type="uri">https://www.ebi.ac.uk/gwas/home</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CARDIoGRAMplusC4D</td>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="http://www.cardiogramplusc4d.org/data-downloads/" ext-link-type="uri">http://www.cardiogramplusc4d.org/data-downloads/</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CDKP/ISGC</td>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://cd.hugeamp.org/downloads.html" ext-link-type="uri">https://cd.hugeamp.org/downloads.html</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CMDKP</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://hugeamp.org/downloads.html" ext-link-type="uri">https://hugeamp.org/downloads.html</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CVDKP</td>
              <td rowspan="1" colspan="1">3</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://cvd.hugeamp.org/downloads.html" ext-link-type="uri">https://cvd.hugeamp.org/downloads.html</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">RGC</td>
              <td rowspan="1" colspan="1">1</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="http://www.reprogen.org/data_download.html" ext-link-type="uri">http://www.reprogen.org/data_download.html</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">PGC</td>
              <td rowspan="1" colspan="1">13</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://www.med.unc.edu/pgc/results-and-downloads" ext-link-type="uri">https://www.med.unc.edu/pgc/results-and-downloads</ext-link>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">SDKP</td>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">
                <ext-link xlink:href="https://sleep.hugeamp.org/downloads.html" ext-link-type="uri">https://sleep.hugeamp.org/downloads.html</ext-link>
              </td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T1TFN1">
            <p>CARDIoGRAMplusC4D: Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) Genetics, CDKP/ISGC: Cerebrovascular Disease Knowledge Portal/International Stroke Genetics Consortium, CMDKP: Common Metabolic Diseases Knowledge Portal, CVDKP: Cardiovascular Disease Knowledge Portal, RGC: Reproductive Genetics Consortium, PGC: Psychiatric Genomic Consortium, SDKP: Sleep Disorder Knowledge Portal.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p><italic toggle="yes">Drug perturbation signatures</italic>. The drug-induced gene expression profiles were retrieved from two sources: the Expanded CMap LINCS Resource 2020 (hereafter referred to as CMap2.0) and the SigCom LINCS resource (<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>). For CMap2.0, we downloaded the level 5 data of small molecule compounds along with the metadata including information of compounds, dosage, time, genes and cell lines. SigCom LINCS is a webserver that provides service to process and analyze over a million gene expression signatures. We downloaded the level 5 data from the SigCom LINCS resource (file name: Automatic Human GEO RNA-seq Signatures; access date: 29 May 2023), which included 4269 signatures that could also be used for connectivity analyses.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Data analysis workflow</title>
      <p>We constructed a standard pipeline to infer genetically-informed drugs. First, because gene expression data could be quite tissue-specific, we defined disease-associated genes using the GWAS data and conducted tissue-specific enrichment analysis (TSEA) to identify disease-relevant tissues for TWAS analyses. Second, we applied TWAS in the predicted tissues and obtained the imputed GReX. Third, we conducted connectivity analyses to infer drug candidates by integrating the GWAS-informed signature (GReX) and drug-induced signatures. Finally, we defined candidate disease-drug pairs by combining the results of the six connectivity methods.</p>
      <sec id="SEC2-2-1">
        <title>Tissue-specific enrichment analysis</title>
        <p>We used Multi-marker Analysis of GenoMic Annotation (<italic toggle="yes">MAGMA v1.10</italic>) (<xref rid="B43" ref-type="bibr">43</xref>) to calculate gene-based p-values using GWAS summary statistics. We defined disease-associated genes as those with MAGMA <italic toggle="yes">P</italic> &lt; 0.05 and conducted TSEA by using the <italic toggle="yes">deTS</italic> algorithm to infer disease-relevant tissues (<xref rid="B44" ref-type="bibr">44</xref>). For each GWAS dataset, <italic toggle="yes">deTS</italic> identified the top three tissues that were most relevant to the disease and had <italic toggle="yes">P</italic> &lt; 0.05. We used these tissues for the following analysis.</p>
      </sec>
      <sec id="SEC2-2-2">
        <title>Transcriptome-wide association study</title>
        <p>To impute the GReX signatures in disease-relevant tissues, we used the TWAS method <italic toggle="yes">S-PrediXcan</italic> in this study (<xref rid="B45" ref-type="bibr">45</xref>). We chose Multivariate adaptive shrinkage (Mashr) models trained using the GTEx data (release v8) as the transcriptome prediction models. For each GWAS dataset, we used <italic toggle="yes">S-PrediXcan</italic> to impute GReX in the top 3 disease-relevant tissues as determined by <italic toggle="yes">deTS</italic>. In addition, we imputed GReX in the whole blood tissue for all diseases regardless of their tissue specific context.</p>
      </sec>
      <sec id="SEC2-2-3">
        <title>Connectivity methods and filtering criteria</title>
        <p>We devised and implemented six distinct connectivity methods to infer drug candidates based on several previous benchmark and retrospective studies (<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B46" ref-type="bibr">46–48</xref>). They were the Weighted Connectivity Score (WTCS), Connection Strength Score (CSS), eXtreme Sum score (XSum) and three types of correlation measurements (Spearman, Pearson and Cosine).</p>
        <p>The method WTCS is used in CMap2.0 and employs the Enrichment Score (ES) used in Gene Set Enrichment Analysis (GSEA) (<xref rid="B30" ref-type="bibr">30</xref>). WTCS is defined as follows:</p>
        <disp-formula>
          <tex-math id="M0001" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{eqnarray*}{\mathrm{WTCS}} = {\mathrm{\;}}\left\{ {\begin{array}{@{}*{1}{c}@{}} {\frac{{\left( {E{S_{up}} - E{S_{down}}} \right)}}{2},\;\;if\;sign\left( {E{S_{up}}} \right)\; \ne sign\left( {E{S_{down}}} \right)}\\ {0,\;\;otherwise} \end{array}} \right.\end{eqnarray*}\end{document}</tex-math>
        </disp-formula>
        <p>where <inline-formula><tex-math id="M0001a" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$E{S_{up}}$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M0002" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$E{S_{down}}$\end{document}</tex-math></inline-formula> are the ESs for upregulated and downregulated gene sets, respectively. The sizes of these gene sets are uniformly defined as 50.</p>
        <p>The method CSS measures the strength of the correlation based on the signed ranks of genes in the disease signature and the drug-induced signature. CSS had been shown to perform superior to other methods when evaluated to assess drug–drug similarities using L1000 data (<xref rid="B46" ref-type="bibr">46</xref>). CSS is defined as follows:</p>
        <disp-formula>
          <tex-math id="M0003" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{eqnarray*}{\mathrm{css}}\left( {\vec R,{\mathrm{S}}} \right) = \;\mathop \sum \limits_{i = 1}^{{N_S}} \left[ {r_{drug}^{abs}\left( {g{s_i}} \right) \times sig{n_{drug}}\left( {g{s_i}} \right)} \right]\end{eqnarray*}\end{document}</tex-math>
        </disp-formula>
        <disp-formula>
          <tex-math id="M0004" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{eqnarray*}{\mathrm{cs}}{{\mathrm{s}}_{max}}\left( {{N_{R,}}{N_S}} \right) = \mathop \sum \limits_{i = 1}^{{N_S}} \left( {{N_R} - i + 1} \right)\end{eqnarray*}\end{document}</tex-math>
        </disp-formula>
        <disp-formula>
          <tex-math id="M0005" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{eqnarray*}{\mathrm{CSS}} = \frac{{{\mathrm{css}}\left( {\vec R,{\mathrm{S}}} \right)}}{{{\mathrm{cs}}{{\mathrm{s}}_{max}}\left( {{N_{R,}}{N_S}} \right)}}\end{eqnarray*}\end{document}</tex-math>
        </disp-formula>
        <p>where <inline-formula><tex-math id="M0006" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\vec R$\end{document}</tex-math></inline-formula> is the rank-ordered drug list, <inline-formula><tex-math id="M0007" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${\mathrm{S}}$\end{document}</tex-math></inline-formula> is the unordered disease signature (50 upregulated genes and 50 downregulated genes), <inline-formula><tex-math id="M0008" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${N_S}$\end{document}</tex-math></inline-formula> is the number of genes in <inline-formula><tex-math id="M0009" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${\mathrm{S}}$\end{document}</tex-math></inline-formula> that appears in <inline-formula><tex-math id="M00010" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\vec R$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="M00011" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g{s_i}$\end{document}</tex-math></inline-formula> is the <italic toggle="yes">i</italic>th gene in the set <inline-formula><tex-math id="M00012" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${\mathrm{S}}$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="M00013" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$r_{drug}^{abs}( {g{s_i}} )$\end{document}</tex-math></inline-formula> is the absolute-value-based ranks of <inline-formula><tex-math id="M00014" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g{s_i}$\end{document}</tex-math></inline-formula> in the drug profile, <inline-formula><tex-math id="M00015" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$sig{n_{drug}}( {g{s_i}} )$\end{document}</tex-math></inline-formula> is the sign of <inline-formula><tex-math id="M00016" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$g{s_i}$\end{document}</tex-math></inline-formula> in <inline-formula><tex-math id="M00017" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\vec R$\end{document}</tex-math></inline-formula>, and <inline-formula><tex-math id="M00018" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${N_R}$\end{document}</tex-math></inline-formula> is the number of genes in <inline-formula><tex-math id="M00019" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\vec R$\end{document}</tex-math></inline-formula>. To generate the non-parametric <italic toggle="yes">P</italic> value of CSS, we randomly select <inline-formula><tex-math id="M00020" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${N_S}$\end{document}</tex-math></inline-formula> genes in <italic toggle="yes">S</italic> and perform 10 000 permutations.</p>
        <p>The method XSum focuses on top- or bottom-ranked genes and has been shown to perform better than other methods in the inference of drug-indication using the CMap data (<xref rid="B13" ref-type="bibr">13</xref>). The XSum score is defined as follows:</p>
        <disp-quote>
          <p><italic toggle="yes">ChangeByCompound</italic> = top <italic toggle="yes">N</italic> upregulated <inline-formula><tex-math id="M00021" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ \cup$\end{document}</tex-math></inline-formula> top N downregulated genes (compound-treated versus no compound-treated)</p>
          <p><italic toggle="yes">XUpInDisease</italic> = N disease-upregulated genes <inline-formula><tex-math id="M00022" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ \cap$\end{document}</tex-math></inline-formula><italic toggle="yes">ChangeByCompound</italic></p>
          <p><italic toggle="yes">XDownInDisease</italic> = N disease-downregulated genes <inline-formula><tex-math id="M00023" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ \cap$\end{document}</tex-math></inline-formula><italic toggle="yes">ChangeByCompound</italic></p>
          <p><italic toggle="yes">Sum(XUpInDisease)</italic> = sum of Z scores (level 5 data) of compound-induced genes in the set <italic toggle="yes">XUpInDisease</italic></p>
          <p><italic toggle="yes">Sum(XDownInDisease)</italic> = sum of Z scores (level 5 data) of compound-induced genes in the set <italic toggle="yes">XDownInDisease</italic></p>
          <p><italic toggle="yes">XSum</italic> = <italic toggle="yes">Sum(XUpInDisease) - Sum(XDownInDisease)</italic></p>
        </disp-quote>
        <p>Similarly, we calculate the p value of XSum by 10 000 permutations of <italic toggle="yes">XUpInDisease</italic> and <italic toggle="yes">XDownInDisease</italic>. In this study, we set <italic toggle="yes">N</italic> to 50.</p>
        <p>In addition, we calculate three metrics of correlation: Spearman Correlation Coefficient (SCC), Pearson Correlation Coefficient (PCC) and Cosine Correlation Score (CCS) using all shared genes between drug-induced profiles and disease-induced profiles. These three metrics can also be extended to the extremely shared genes between the sets of genes most perturbed (50 upregulated genes + 50 downregulated genes) by the drug and disease (XPearson: eXtreme Pearson correlation; XSpearman: eXtreme Spearman rank correlation; XCosine: eXtreme Cosine correlation).</p>
        <p>With the results of all the six connectivity methods, we define the candidate disease-drug pairs to be included in our database according to the following criteria:</p>
        <p><italic toggle="yes">WTCS &lt; 0 &amp; CSS &lt; 0 &amp; CSS p &lt; 0.05 &amp; XSum &lt; 0 &amp; XSum p &lt; 0.05 &amp; SCC &lt; 0 &amp; PCC &lt; 0 &amp; CCS &lt; 0</italic>.</p>
        <p>Furthermore, to amalgamate the significance derived from all six connectivity methods, we propose a meta-score calculated as the count of methods that identify the correlation with high priority. Specifically, for each dataset-tissue pair, we rank all candidate drugs by their scores from each method. A drug is considered identified with high priority by a method if it is ranked among the top 5% of all candidates by the corresponding method. As a result, each drug receives 6 labels, each indicating whether it is of high priority or not according to each of the six methods. Notably, the range of the meta-score is between 0 and 6 for a total of 6 methods.</p>
      </sec>
    </sec>
    <sec id="SEC2-3">
      <title>Database implementation</title>
      <p>PharmGWAS was deployed in a virtual machine with a CentOS 7.9 environment. Nginx v1.20.1 (<ext-link xlink:href="https://nginx.org/en/" ext-link-type="uri">https://nginx.org/en/</ext-link>) was used as an HTTP and reverse proxy server. We used MySQL (<ext-link xlink:href="https://www.mysql.com" ext-link-type="uri">https://www.mysql.com</ext-link>) as the database engine. The backend RESTful web service was built with Java Spring Boot framework (<ext-link xlink:href="https://spring.io/projects/spring-boot" ext-link-type="uri">https://spring.io/projects/spring-boot</ext-link>). The frontend of the web interface was developed using React (<ext-link xlink:href="https://reactjs.org" ext-link-type="uri">https://reactjs.org</ext-link>) and organized using the UMI (<ext-link xlink:href="https://umijs.org" ext-link-type="uri">https://umijs.org</ext-link>) framework. For the user interface (UI) library, we chose Ant Design (<ext-link xlink:href="https://ant.design" ext-link-type="uri">https://ant.design</ext-link>), which contained a set of high-quality components that could be easily extended to build rich and interactive user interfaces. In addition, the interactive visualization of charts was achieved by using different libraries such as HighCharts (<ext-link xlink:href="https://www.highcharts.com" ext-link-type="uri">https://www.highcharts.com</ext-link>) and ECharts (<ext-link xlink:href="https://echarts.apache.org" ext-link-type="uri">https://echarts.apache.org</ext-link>).</p>
    </sec>
  </sec>
  <sec id="SEC3">
    <title>Database content and usage</title>
    <sec id="SEC3-1">
      <title>Overview of PharmGWAS</title>
      <p>PharmGWAS aims to translate GWAS signals into clinical practice. Currently, PharmGWAS contains 1929 GWAS datasets curated from GWAS Catalog, UKBB and several large consortiums. Moreover, 720216 compound-perturbed gene expression signatures were collected from CMap2.0 and an additional 4269 perturbed signatures were collected from GEO. We implemented our standard pipeline to infer candidate disease-drug pairs for each GWAS dataset. The outline of PharmGWAS is illustrated in Figure <xref rid="F1" ref-type="fig">1</xref>. Currently, PharmGWAS deposits a total of 732947 genetically-informed disease-drug pairs derived from CMap signatures and 7280 pairs from GEO signatures, totaling 740227 (732947 + 7280) disease-drug pairs. Among them, 81.58% (603 874) have a meta-score of 0, 11.40% (84411) have a meta-score of 1, 3.52% (26 021) have 2, 2.89% (21 370) have 3, 0.49% (3652) have 4, 838 have 5, and 61 have 6. In all web pages, the default rule for sorting results is based on the meta-score in descending order. To the best of our knowledge, PharmGWAS is the first systematic and comprehensive database to identify drug repurposing candidates for nearly all available disease traits.</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Schematic overview of PharmGWAS. TSEA: Tissue-Specific Enrichment Analysis. TWAS: Transcriptome Wide Association Studies. GEO: Gene Expression Omnibus. WTCS: Weighted Connectivity Score. CSS: Connection Strength Score. XSum: The eXtreme Sum score.</p>
        </caption>
        <graphic xlink:href="gkad832fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-2">
      <title>Web interface</title>
      <p>PharmGWAS provides a user-friendly interface that allows users to intuitively search, browse and download any results in the database (Figure <xref rid="F2" ref-type="fig">2</xref>). The search function available in the homepage supports keyword-based quick queries for multiple forms of items, such as names of diseases, CMap signatures, or GEO signatures (Figure <xref rid="F2" ref-type="fig">2A</xref>). Meanwhile, users can navigate the entire database through three featured modules: Browse, CMap Results and GEO Results. All processed data in PharmGWAS are freely accessible.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Screenshots of the major web pages for PharmGWAS. (<bold>A</bold>) The homepage search function allows users to quickly query for multiple items including GWAS datasets, CMap signatures and GEO signatures. (<bold>B</bold>) The browse module provides multi-criteria search function to further filter the data of interest. (<bold>C</bold>) Detailed browse page for an individual GWAS dataset. Clicking on the ‘Association ID’ will direct users to view the detailed results and charts for corresponding item and clicking on the ‘CMap Name’ will lead to the PubChem for specific information. (<bold>D</bold>) The detail results page for each candidate disease–drug pair. (<bold>E</bold>) The CMap Results and GEO Results modules.</p>
        </caption>
        <graphic xlink:href="gkad832fig2" position="float"/>
      </fig>
      <p>The Browse module comprises three pages to facilitate exploration of GWAS datasets, CMap signatures and GEO signatures. A series of extended interactive functional modules, such as multi-criteria search and download, are designed to enable users to quickly retrieve relevant data of interest (Figure <xref rid="F2" ref-type="fig">2B</xref>). The Browse page of ‘GWAS datasets’ stores a large amount of key meta information, including data source, disease name, publish year, the sample size of GWAS, the number of cases, the number of controls and so on. The Browse pages of ‘CMap signatures’ and ‘GEO signatures’ also contain a lot of meta information, such as signature name, mechanism of action (MOA), Canonical SMILES, InChiKey, cell line, dose and GEO accession ID and so on. It is worth noting that clicking on the corresponding ‘Dataset Name’ or ‘Signature ID’ button on the row of interest would direct users to a new ‘detail page’ to view detailed results for a specific GWAS dataset or signature. The detail page for a GWAS dataset displays the meta-information about the study, the disease-relevant tissues identified by <italic toggle="yes">deTS</italic> and the drug candidates derived from CMap signatures and GEO signatures (Figure <xref rid="F2" ref-type="fig">2C</xref>). Furthermore, users can filter the results by entering and selecting keywords about the tissue, CMap name, or GEO accession ID. More explanatory information about the column can be viewed by hovering over each entry of table headers and clicking on the header will sort the table by the selected column. By clicking on the ‘CMap Name’ column, users can access the details of the corresponding compound in PubChem (<xref rid="B49" ref-type="bibr">49</xref>), such as chemical and physical properties, clinical trials, consolidated references, patents and so on. By clicking on the ‘Association ID’ column, users will be directed to a dedicated page with detailed results and charts for the item (Figure <xref rid="F2" ref-type="fig">2C</xref>).</p>
      <p>The ‘detail page’ about individual disease-drug pairs contains five sections (Figure <xref rid="F2" ref-type="fig">2D</xref>). First, meta-information about the corresponding disease and drug is shown at the top of the page. Second, we use a radargram to provide an overview of the results from all six connectivity methods. The larger the area enclosed by the results of the six methods, the more reliable the drug candidate is. Third, to assess whether the disease-upregulated genes appear toward the bottom of drug-induced profiles and disease-downregulated genes appear toward the top of drug-induced profiles, the GSEA plots of disease upregulated and downregulated genes in the pre-ranked list of drug signature are provided. Next, the reverse intersection analysis of disease-upregulated genes with drug-downregulated genes is illustrated in Venn diagrams, and similarly for disease-downregulated genes with drug-upregulated genes. Finally, the corresponding Z scores of upregulated and downregulated genes in disease and drug signatures are displayed in the histograms.</p>
      <p>The modules for ‘CMap Results’ and ‘GEO Results’ provide an opportunity to directly search for disease-drug pairs across datasets and signatures (Figure <xref rid="F2" ref-type="fig">2E</xref>). An advanced search function has also been provided. Users can jump to the detail page of disease-drug pairs by clicking on the ‘Association ID’ in the CMap Results and GEO Results pages. In addition, all processed results can be freely downloaded.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Application of PharmGWAS: coronary artery disease as an example</title>
      <p>We take the GWAS dataset of coronary artery disease (CAD) reported by Webb <italic toggle="yes">et al.</italic> (<xref rid="B50" ref-type="bibr">50</xref>) as a case study to demonstrate the application of PharmGWAS (Figure <xref rid="F2" ref-type="fig">2C</xref> and <xref rid="F2" ref-type="fig">D</xref>). CAD is a leading cause of death worldwide with a major heritable component and GWAS has identified ∼60 loci explaining ∼15% of the heritability. The three tissues mostly associated with CAD as determined by using MAGMA and <italic toggle="yes">deTS</italic> were artery coronary (<italic toggle="yes">P</italic> = 0.0070), liver (<italic toggle="yes">P</italic> = 0.0242) and spleen (<italic toggle="yes">P</italic> = 0.0242). We calculated GReX in these three tissues as well as in the whole blood. After connectivity analyses with CMap2.0 signatures, the top-ranked drug candidate was lisofylline (WTCS = −0.5730, XSum = −9.3722, XSum <italic toggle="yes">P</italic> &lt; 1 × 10<sup>−5</sup>, CSS = −0.1464, CSS <italic toggle="yes">P</italic> = 0.0101, SCC = −0.1478, PCC = −0.1996, CCS = −0.1998) in artery coronary (Figure <xref rid="F2" ref-type="fig">2C</xref>). Lisofylline was originally designed as an anti-inflammatory agent and had been investigated for the therapy of diabetes (<xref rid="B51" ref-type="bibr">51</xref>). It had been reported to have suppressive effects on the serum-free fatty acids (<xref rid="B52" ref-type="bibr">52</xref>), a risk factor of atherosclerosis and atherosclerosis was a major complication of diabetes (<xref rid="B53" ref-type="bibr">53</xref>). Besides, pentoxifylline, a methylxanthine derivative of lisofylline, had been proven to have therapeutic benefits on atherosclerosis (<xref rid="B54" ref-type="bibr">54</xref>). Taken together, lisofylline is a reliable candidate drug for the treatment of CAD. These results suggested PharmGWAS could serve as a valuable resource for drug repurposing by leveraging the discovery power of human genetics data.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion and future developments</title>
    <p>In this study, we developed PharmGWAS, a GWAS-based knowledgebase for drug repurposing by incorporating human genetics data and drug perturbation data. To the best of our knowledge, PharmGWAS is the first valuable reference resource that provides the analysis results processed by a unified drug repurposing workflow for thousands of publicly available disease-relevant GWAS datasets. In addition to the wide range of disease types covered by GWAS datasets from multiple sources, the drug perturbation data retrieved from CMap2.0 and the GEO RNA-seq signatures extracted from SigCom LINCS are among the most comprehensive. Our results shed new light on drug discovery, drug combination, drug resistance and drug side effects from the human genetics perspective.</p>
    <p>With the accumulation of new GWAS datasets with increasing amounts of samples, PharmGWAS will be continuously updated by collecting and processing the latest available genetic data. In particular, our results are restricted solely to scientific studies and do not constitute any clinical recommendations. Because of the varying quality of the GWAS datasets and imputed GReX, caution is required in interpreting our results. Moreover, because CMap data are limited to a selection of cell lines rather than tissues, further efforts to expand the repertoire of tissues will enhance the reliability of our results. Lastly, population-scale applications of single-cell sequencing is becoming possible with the development of single-cell sequencing technology and decreasing costs (<xref rid="B55" ref-type="bibr">55–57</xref>). Thus, we anticipate that our framework for drug repurposing based on the TWAS concept will expand at single-cell resolution in the future.</p>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We thank National Genomics Data Center (NGDC) for providing support in database deployment. We are grateful to all members of the Laboratory for Precision Health (LPH) for their valuable comments.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>PharmGWAS is available at <ext-link xlink:href="https://ngdc.cncb.ac.cn/pharmgwas" ext-link-type="uri">https://ngdc.cncb.ac.cn/pharmgwas</ext-link>. Users can freely access all processed data and results through the web service.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>National Natural Science Foundation of China [32270706]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB38010400]; Startup Research Fund of Henan Academy of Sciences [232016009]. Funding for open access charge: National Natural Science Foundation of China [32270706] and Strategic Priority Research Program of Chinese Academy of Sciences [XDB38010400 to P.J.].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Waring</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Arrowsmith</surname><given-names>J.</given-names></string-name>, <string-name><surname>Leach</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Leeson</surname><given-names>P.D.</given-names></string-name>, <string-name><surname>Mandrell</surname><given-names>S.</given-names></string-name>, <string-name><surname>Owen</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Pairaudeau</surname><given-names>G.</given-names></string-name>, <string-name><surname>Pennie</surname><given-names>W.D.</given-names></string-name>, <string-name><surname>Pickett</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>An analysis of the attrition of drug candidates from four major pharmaceutical companies</article-title>. <source>Nat. Rev. Drug Discov.</source><year>2015</year>; <volume>14</volume>:<fpage>475</fpage>–<lpage>486</lpage>.<pub-id pub-id-type="pmid">26091267</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dowden</surname><given-names>H.</given-names></string-name>, <string-name><surname>Munro</surname><given-names>J.</given-names></string-name></person-group><article-title>Trends in clinical success rates and therapeutic focus</article-title>. <source>Nat. Rev. Drug. Discov.</source><year>2019</year>; <volume>18</volume>:<fpage>495</fpage>–<lpage>496</lpage>.<pub-id pub-id-type="pmid">31267067</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pushpakom</surname><given-names>S.</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F.</given-names></string-name>, <string-name><surname>Eyers</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Escott</surname><given-names>K.J.</given-names></string-name>, <string-name><surname>Hopper</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wells</surname><given-names>A.</given-names></string-name>, <string-name><surname>Doig</surname><given-names>A.</given-names></string-name>, <string-name><surname>Guilliams</surname><given-names>T.</given-names></string-name>, <string-name><surname>Latimer</surname><given-names>J.</given-names></string-name>, <string-name><surname>McNamee</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Drug repurposing: progress, challenges and recommendations</article-title>. <source>Nat. Rev. Drug. Discov.</source><year>2019</year>; <volume>18</volume>:<fpage>41</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">30310233</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kunkel</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Suneja</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ebert</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Bongers</surname><given-names>K.S.</given-names></string-name>, <string-name><surname>Fox</surname><given-names>D.K.</given-names></string-name>, <string-name><surname>Malmberg</surname><given-names>S.E.</given-names></string-name>, <string-name><surname>Alipour</surname><given-names>F.</given-names></string-name>, <string-name><surname>Shields</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Adams</surname><given-names>C.M.</given-names></string-name></person-group><article-title>mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass</article-title>. <source>Cell Metab.</source><year>2011</year>; <volume>13</volume>:<fpage>627</fpage>–<lpage>638</lpage>.<pub-id pub-id-type="pmid">21641545</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Ciou</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>S.T.</given-names></string-name>, <string-name><surname>Kok</surname><given-names>V.C.</given-names></string-name>, <string-name><surname>Chung</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Tsai</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Kurubanjerdjit</surname><given-names>N.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>C.F.</given-names></string-name>, <string-name><surname>Ng</surname><given-names>K.L.</given-names></string-name></person-group><article-title>Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular smooth muscle cells</article-title>. <source>PeerJ</source>. <year>2016</year>; <volume>4</volume>:<fpage>e2478</fpage>.<pub-id pub-id-type="pmid">27703845</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Malcomson</surname><given-names>B.</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>H.</given-names></string-name>, <string-name><surname>Veglia</surname><given-names>E.</given-names></string-name>, <string-name><surname>Thillaiyampalam</surname><given-names>G.</given-names></string-name>, <string-name><surname>Barsden</surname><given-names>R.</given-names></string-name>, <string-name><surname>Donegan</surname><given-names>S.</given-names></string-name>, <string-name><surname>El Banna</surname><given-names>A.</given-names></string-name>, <string-name><surname>Elborn</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Ennis</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2016</year>; <volume>113</volume>:<fpage>E3725</fpage>–<lpage>E3734</lpage>.<pub-id pub-id-type="pmid">27286825</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Raghavan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Hyter</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pathak</surname><given-names>H.B.</given-names></string-name>, <string-name><surname>Godwin</surname><given-names>A.K.</given-names></string-name>, <string-name><surname>Konecny</surname><given-names>G.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Goode</surname><given-names>E.L.</given-names></string-name>, <string-name><surname>Fridley</surname><given-names>B.L.</given-names></string-name></person-group><article-title>Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer</article-title>. <source>Bmc Genomics [Electronic Resource]</source>. <year>2016</year>; <volume>17</volume>:<fpage>811</fpage>.<pub-id pub-id-type="pmid">27756228</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mirza</surname><given-names>N.</given-names></string-name>, <string-name><surname>Sills</surname><given-names>G.J.</given-names></string-name>, <string-name><surname>Pirmohamed</surname><given-names>M.</given-names></string-name>, <string-name><surname>Marson</surname><given-names>A.G.</given-names></string-name></person-group><article-title>Identifying new antiepileptic drugs through genomics-based drug repurposing</article-title>. <source>Hum. Mol. Genet.</source><year>2017</year>; <volume>26</volume>:<fpage>527</fpage>–<lpage>537</lpage>.<pub-id pub-id-type="pmid">28053048</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Williams</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gatt</surname><given-names>A.</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>E.</given-names></string-name>, <string-name><surname>Corcoran</surname><given-names>J.</given-names></string-name>, <string-name><surname>Doherty</surname><given-names>P.</given-names></string-name>, <string-name><surname>Chambers</surname><given-names>D.</given-names></string-name>, <string-name><surname>Ballard</surname><given-names>C.</given-names></string-name></person-group><article-title>Drug repurposing for Alzheimer's disease based on transcriptional profiling of human iPSC-derived cortical neurons</article-title>. <source>Transl Psychiatry</source>. <year>2019</year>; <volume>9</volume>:<fpage>220</fpage>.<pub-id pub-id-type="pmid">31492831</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y.Y.</given-names></string-name>, <string-name><surname>Kang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Hao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Bao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Jia</surname><given-names>P.</given-names></string-name></person-group><article-title>CeDR Atlas: a knowledgebase of cellular drug response</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1164</fpage>–<lpage>D1171</lpage>.<pub-id pub-id-type="pmid">34634794</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lamb</surname><given-names>J.</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>E.D.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.</given-names></string-name>, <string-name><surname>Modell</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Blat</surname><given-names>I.C.</given-names></string-name>, <string-name><surname>Wrobel</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Lerner</surname><given-names>J.</given-names></string-name>, <string-name><surname>Brunet</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ross</surname><given-names>K.N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease</article-title>. <source>Science</source>. <year>2006</year>; <volume>313</volume>:<fpage>1929</fpage>–<lpage>1935</lpage>.<pub-id pub-id-type="pmid">17008526</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Gant</surname><given-names>T.W.</given-names></string-name></person-group><article-title>A simple and robust method for connecting small-molecule drugs using gene-expression signatures</article-title>. <source>BMC Bioinf.</source><year>2008</year>; <volume>9</volume>:<fpage>258</fpage>.</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>V.</given-names></string-name>, <string-name><surname>Agarwal</surname><given-names>P.</given-names></string-name></person-group><article-title>Systematic evaluation of connectivity map for disease indications</article-title>. <source>Genome Med.</source><year>2014</year>; <volume>6</volume>:<fpage>540</fpage>.<pub-id pub-id-type="pmid">25606058</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szustakowski</surname><given-names>J.D.</given-names></string-name>, <string-name><surname>Balasubramanian</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kvikstad</surname><given-names>E.</given-names></string-name>, <string-name><surname>Khalid</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bronson</surname><given-names>P.G.</given-names></string-name>, <string-name><surname>Sasson</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>E.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Wade Davis</surname><given-names>J.</given-names></string-name>, <string-name><surname>Haefliger</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank</article-title>. <source>Nat. Genet.</source><year>2021</year>; <volume>53</volume>:<fpage>942</fpage>–<lpage>948</lpage>.<pub-id pub-id-type="pmid">34183854</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reay</surname><given-names>W.R.</given-names></string-name>, <string-name><surname>Cairns</surname><given-names>M.J.</given-names></string-name></person-group><article-title>Advancing the use of genome-wide association studies for drug repurposing</article-title>. <source>Nat. Rev. Genet.</source><year>2021</year>; <volume>22</volume>:<fpage>658</fpage>–<lpage>671</lpage>.<pub-id pub-id-type="pmid">34302145</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carss</surname><given-names>K.J.</given-names></string-name>, <string-name><surname>Deaton</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>Del Rio-Espinola</surname><given-names>A.</given-names></string-name>, <string-name><surname>Diogo</surname><given-names>D.</given-names></string-name>, <string-name><surname>Fielden</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kulkarni</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Moggs</surname><given-names>J.</given-names></string-name>, <string-name><surname>Newham</surname><given-names>P.</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Sistare</surname><given-names>F.D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Using human genetics to improve safety assessment of therapeutics</article-title>. <source>Nat. Rev. Drug. Discov.</source><year>2023</year>; <volume>22</volume>:<fpage>145</fpage>–<lpage>162</lpage>.<pub-id pub-id-type="pmid">36261593</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ochoa</surname><given-names>D.</given-names></string-name>, <string-name><surname>Karim</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ghoussaini</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hulcoop</surname><given-names>D.G.</given-names></string-name>, <string-name><surname>McDonagh</surname><given-names>E.M.</given-names></string-name>, <string-name><surname>Dunham</surname><given-names>I.</given-names></string-name></person-group><article-title>Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs</article-title>. <source>Nat. Rev. Drug. Discov.</source><year>2022</year>; <volume>21</volume>:<fpage>551</fpage>.<pub-id pub-id-type="pmid">35804044</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nelson</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Tipney</surname><given-names>H.</given-names></string-name>, <string-name><surname>Painter</surname><given-names>J.L.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Nicoletti</surname><given-names>P.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Floratos</surname><given-names>A.</given-names></string-name>, <string-name><surname>Sham</surname><given-names>P.C.</given-names></string-name>, <string-name><surname>Li</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The support of human genetic evidence for approved drug indications</article-title>. <source>Nat. Genet.</source><year>2015</year>; <volume>47</volume>:<fpage>856</fpage>–<lpage>860</lpage>.<pub-id pub-id-type="pmid">26121088</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Okada</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Trynka</surname><given-names>G.</given-names></string-name>, <string-name><surname>Raj</surname><given-names>T.</given-names></string-name>, <string-name><surname>Terao</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ikari</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kochi</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ohmura</surname><given-names>K.</given-names></string-name>, <string-name><surname>Suzuki</surname><given-names>A.</given-names></string-name>, <string-name><surname>Yoshida</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genetics of rheumatoid arthritis contributes to biology and drug discovery</article-title>. <source>Nature</source>. <year>2014</year>; <volume>506</volume>:<fpage>376</fpage>–<lpage>381</lpage>.<pub-id pub-id-type="pmid">24390342</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Plenge</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Scolnick</surname><given-names>E.M.</given-names></string-name>, <string-name><surname>Altshuler</surname><given-names>D</given-names></string-name></person-group><article-title>Validating therapeutic targets through human genetics</article-title>. <source>Nat. Rev. Drug. Discov.</source><year>2013</year>; <volume>12</volume>:<fpage>581</fpage>–<lpage>594</lpage>.<pub-id pub-id-type="pmid">23868113</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Duerr</surname><given-names>R.H.</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>K.D.</given-names></string-name>, <string-name><surname>Brant</surname><given-names>S.R.</given-names></string-name>, <string-name><surname>Rioux</surname><given-names>J.D.</given-names></string-name>, <string-name><surname>Silverberg</surname><given-names>M.S.</given-names></string-name>, <string-name><surname>Daly</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Steinhart</surname><given-names>A.H.</given-names></string-name>, <string-name><surname>Abraham</surname><given-names>C.</given-names></string-name>, <string-name><surname>Regueiro</surname><given-names>M.</given-names></string-name>, <string-name><surname>Griffiths</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A genome-wide association study identifies IL23R as an inflammatory bowel disease gene</article-title>. <source>Science</source>. <year>2006</year>; <volume>314</volume>:<fpage>1461</fpage>–<lpage>1463</lpage>.<pub-id pub-id-type="pmid">17068223</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feagan</surname><given-names>B.G.</given-names></string-name>, <string-name><surname>Sandborn</surname><given-names>W.J.</given-names></string-name>, <string-name><surname>Gasink</surname><given-names>C.</given-names></string-name>, <string-name><surname>Jacobstein</surname><given-names>D.</given-names></string-name>, <string-name><surname>Lang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Friedman</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Blank</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Johanns</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>L.L.</given-names></string-name>, <string-name><surname>Miao</surname><given-names>Y.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease</article-title>. <source>N. Engl. J. Med.</source><year>2016</year>; <volume>375</volume>:<fpage>1946</fpage>–<lpage>1960</lpage>.<pub-id pub-id-type="pmid">27959607</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Wacholder</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gail</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Peters</surname><given-names>U.</given-names></string-name>, <string-name><surname>Jacobs</surname><given-names>K.B.</given-names></string-name>, <string-name><surname>Chanock</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Chatterjee</surname><given-names>N.</given-names></string-name></person-group><article-title>Estimation of effect size distribution from genome-wide association studies and implications for future discoveries</article-title>. <source>Nat. Genet.</source><year>2010</year>; <volume>42</volume>:<fpage>570</fpage>–<lpage>575</lpage>.<pub-id pub-id-type="pmid">20562874</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>UCLEB Consortium</collab><string-name><surname>Speed</surname><given-names>D.</given-names></string-name>, <string-name><surname>Cai</surname><given-names>N.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Nejentsev</surname><given-names>S.</given-names></string-name>, <string-name><surname>Balding</surname><given-names>D.J.</given-names></string-name></person-group><article-title>Reevaluation of SNP heritability in complex human traits</article-title>. <source>Nat. Genet.</source><year>2017</year>; <volume>49</volume>:<fpage>986</fpage>–<lpage>992</lpage>.<pub-id pub-id-type="pmid">28530675</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Goddard</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Wray</surname><given-names>N.R.</given-names></string-name>, <string-name><surname>Visscher</surname><given-names>P.M.</given-names></string-name></person-group><article-title>Concepts, estimation and interpretation of SNP-based heritability</article-title>. <source>Nat. Genet.</source><year>2017</year>; <volume>49</volume>:<fpage>1304</fpage>–<lpage>1310</lpage>.<pub-id pub-id-type="pmid">28854176</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khera</surname><given-names>A.V.</given-names></string-name>, <string-name><surname>Chaffin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Aragam</surname><given-names>K.G.</given-names></string-name>, <string-name><surname>Haas</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Roselli</surname><given-names>C.</given-names></string-name>, <string-name><surname>Choi</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Natarajan</surname><given-names>P.</given-names></string-name>, <string-name><surname>Lander</surname><given-names>E.S.</given-names></string-name>, <string-name><surname>Lubitz</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Ellinor</surname><given-names>P.T.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations</article-title>. <source>Nat. Genet.</source><year>2018</year>; <volume>50</volume>:<fpage>1219</fpage>–<lpage>1224</lpage>.<pub-id pub-id-type="pmid">30104762</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>So</surname><given-names>H.C.</given-names></string-name>, <string-name><surname>Chau</surname><given-names>C.K.</given-names></string-name>, <string-name><surname>Chiu</surname><given-names>W.T.</given-names></string-name>, <string-name><surname>Ho</surname><given-names>K.S.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>C.P.</given-names></string-name>, <string-name><surname>Yim</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Sham</surname><given-names>P.C.</given-names></string-name></person-group><article-title>Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry</article-title>. <source>Nat. Neurosci.</source><year>2017</year>; <volume>20</volume>:<fpage>1342</fpage>–<lpage>1349</lpage>.<pub-id pub-id-type="pmid">28805813</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Woodward</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Thorp</surname><given-names>J.G.</given-names></string-name>, <string-name><surname>Akosile</surname><given-names>W.</given-names></string-name>, <string-name><surname>Ong</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Gamazon</surname><given-names>E.R.</given-names></string-name>, <string-name><surname>Derks</surname><given-names>E.M.</given-names></string-name>, <string-name><surname>Gerring</surname><given-names>Z.F.</given-names></string-name></person-group><article-title>Identification of drug repurposing candidates for the treatment of anxiety: a genetic approach</article-title>. <source>Psychiatry Res.</source><year>2023</year>; <volume>326</volume>:<fpage>115343</fpage>.<pub-id pub-id-type="pmid">37473490</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>P.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Kerchberger</surname><given-names>V.E.</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>S.D.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>B.</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>T.L.</given-names></string-name>, <string-name><surname>Cox</surname><given-names>N.J.</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Stein</surname><given-names>C.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension</article-title>. <source>Nat. Commun.</source><year>2022</year>; <volume>13</volume>:<fpage>46</fpage>.<pub-id pub-id-type="pmid">35013250</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.D.</given-names></string-name>, <string-name><surname>Natoli</surname><given-names>T.E.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Gould</surname><given-names>J.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Tubelli</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Asiedu</surname><given-names>J.K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles</article-title>. <source>Cell</source>. <year>2017</year>; <volume>171</volume>:<fpage>1437</fpage>–<lpage>1452</lpage>.<pub-id pub-id-type="pmid">29195078</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Evangelista</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>D.J.B.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Lachmann</surname><given-names>A.</given-names></string-name>, <string-name><surname>Jeon</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>K.</given-names></string-name>, <string-name><surname>Jagodnik</surname><given-names>K.M.</given-names></string-name>, <string-name><surname>Jenkins</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Kuleshov</surname><given-names>M.V.</given-names></string-name>, <string-name><surname>Wojciechowicz</surname><given-names>M.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>SigCom LINCS: data and metadata search engine for a million gene expression signatures</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>W697</fpage>–<lpage>W709</lpage>.<pub-id pub-id-type="pmid">35524556</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sollis</surname><given-names>E.</given-names></string-name>, <string-name><surname>Mosaku</surname><given-names>A.</given-names></string-name>, <string-name><surname>Abid</surname><given-names>A.</given-names></string-name>, <string-name><surname>Buniello</surname><given-names>A.</given-names></string-name>, <string-name><surname>Cerezo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Gil</surname><given-names>L.</given-names></string-name>, <string-name><surname>Groza</surname><given-names>T.</given-names></string-name>, <string-name><surname>Gunes</surname><given-names>O.</given-names></string-name>, <string-name><surname>Hall</surname><given-names>P.</given-names></string-name>, <string-name><surname>Hayhurst</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D977</fpage>–<lpage>D985</lpage>.<pub-id pub-id-type="pmid">36350656</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sudlow</surname><given-names>C.</given-names></string-name>, <string-name><surname>Gallacher</surname><given-names>J.</given-names></string-name>, <string-name><surname>Allen</surname><given-names>N.</given-names></string-name>, <string-name><surname>Beral</surname><given-names>V.</given-names></string-name>, <string-name><surname>Burton</surname><given-names>P.</given-names></string-name>, <string-name><surname>Danesh</surname><given-names>J.</given-names></string-name>, <string-name><surname>Downey</surname><given-names>P.</given-names></string-name>, <string-name><surname>Elliott</surname><given-names>P.</given-names></string-name>, <string-name><surname>Green</surname><given-names>J.</given-names></string-name>, <string-name><surname>Landray</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age</article-title>. <source>PLoS Med.</source><year>2015</year>; <volume>12</volume>:<fpage>e1001779</fpage>.<pub-id pub-id-type="pmid">25826379</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nelson</surname><given-names>C.P.</given-names></string-name>, <string-name><surname>Goel</surname><given-names>A.</given-names></string-name>, <string-name><surname>Butterworth</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Kanoni</surname><given-names>S.</given-names></string-name>, <string-name><surname>Webb</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Marouli</surname><given-names>E.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ntalla</surname><given-names>I.</given-names></string-name>, <string-name><surname>Lai</surname><given-names>F.Y.</given-names></string-name>, <string-name><surname>Hopewell</surname><given-names>J.C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Association analyses based on false discovery rate implicate new loci for coronary artery disease</article-title>. <source>Nat. Genet.</source><year>2017</year>; <volume>49</volume>:<fpage>1385</fpage>–<lpage>1391</lpage>.<pub-id pub-id-type="pmid">28714975</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Traylor</surname><given-names>M.</given-names></string-name>, <string-name><surname>Malik</surname><given-names>R.</given-names></string-name>, <string-name><surname>Nalls</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Cotlarciuc</surname><given-names>I.</given-names></string-name>, <string-name><surname>Radmanesh</surname><given-names>F.</given-names></string-name>, <string-name><surname>Thorleifsson</surname><given-names>G.</given-names></string-name>, <string-name><surname>Hanscombe</surname><given-names>K.B.</given-names></string-name>, <string-name><surname>Langefeld</surname><given-names>C.</given-names></string-name>, <string-name><surname>Saleheen</surname><given-names>D.</given-names></string-name>, <string-name><surname>Rost</surname><given-names>N.S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genetic variation at 16q24.2 is associated with small vessel stroke</article-title>. <source>Ann. Neurol.</source><year>2017</year>; <volume>81</volume>:<fpage>383</fpage>–<lpage>394</lpage>.<pub-id pub-id-type="pmid">27997041</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sandholm</surname><given-names>N.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Nair</surname><given-names>V.</given-names></string-name>, <string-name><surname>Sheng</surname><given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ahlqvist</surname><given-names>E.</given-names></string-name>, <string-name><surname>van Zuydam</surname><given-names>N.</given-names></string-name>, <string-name><surname>Dahlstrom</surname><given-names>E.H.</given-names></string-name>, <string-name><surname>Fermin</surname><given-names>D.</given-names></string-name>, <string-name><surname>Smyth</surname><given-names>L.J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease</article-title>. <source>Diabetologia</source>. <year>2022</year>; <volume>65</volume>:<fpage>1495</fpage>–<lpage>1509</lpage>.<pub-id pub-id-type="pmid">35763030</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roselli</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>M.</given-names></string-name>, <string-name><surname>Nauffal</surname><given-names>V.</given-names></string-name>, <string-name><surname>Georges</surname><given-names>A.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Love</surname><given-names>K.</given-names></string-name>, <string-name><surname>Weng</surname><given-names>L.C.</given-names></string-name>, <string-name><surname>Delling</surname><given-names>F.N.</given-names></string-name>, <string-name><surname>Maurya</surname><given-names>S.R.</given-names></string-name>, <string-name><surname>Schrolkamp</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse</article-title>. <source>Eur. Heart J.</source><year>2022</year>; <volume>43</volume>:<fpage>1668</fpage>–<lpage>1680</lpage>.<pub-id pub-id-type="pmid">35245370</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nauffal</surname><given-names>V.</given-names></string-name>, <string-name><surname>Di Achille</surname><given-names>P.</given-names></string-name>, <string-name><surname>Klarqvist</surname><given-names>M.D.R.</given-names></string-name>, <string-name><surname>Cunningham</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Hill</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Pirruccello</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Weng</surname><given-names>L.C.</given-names></string-name>, <string-name><surname>Morrill</surname><given-names>V.N.</given-names></string-name>, <string-name><surname>Choi</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Khurshid</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genetics of myocardial interstitial fibrosis in the human heart and association with disease</article-title>. <source>Nat. Genet.</source><year>2023</year>; <volume>55</volume>:<fpage>777</fpage>–<lpage>786</lpage>.<pub-id pub-id-type="pmid">37081215</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ruth</surname><given-names>K.S.</given-names></string-name>, <string-name><surname>Day</surname><given-names>F.R.</given-names></string-name>, <string-name><surname>Hussain</surname><given-names>J.</given-names></string-name>, <string-name><surname>Martinez-Marchal</surname><given-names>A.</given-names></string-name>, <string-name><surname>Aiken</surname><given-names>C.E.</given-names></string-name>, <string-name><surname>Azad</surname><given-names>A.</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Knoblochova</surname><given-names>L.</given-names></string-name>, <string-name><surname>Abe</surname><given-names>H.</given-names></string-name>, <string-name><surname>Tarry-Adkins</surname><given-names>J.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genetic insights into biological mechanisms governing human ovarian ageing</article-title>. <source>Nature</source>. <year>2021</year>; <volume>596</volume>:<fpage>393</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">34349265</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mullins</surname><given-names>N.</given-names></string-name>, <string-name><surname>Forstner</surname><given-names>A.J.</given-names></string-name>, <string-name><surname>O’Connell</surname><given-names>K.S.</given-names></string-name>, <string-name><surname>Coombes</surname><given-names>B.</given-names></string-name>, <string-name><surname>Coleman</surname><given-names>J.R.I.</given-names></string-name>, <string-name><surname>Qiao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Als</surname><given-names>T.D.</given-names></string-name>, <string-name><surname>Bigdeli</surname><given-names>T.B.</given-names></string-name>, <string-name><surname>Borte</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bryois</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology</article-title>. <source>Nat. Genet.</source><year>2021</year>; <volume>53</volume>:<fpage>817</fpage>–<lpage>829</lpage>.<pub-id pub-id-type="pmid">34002096</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cade</surname><given-names>B.E.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.</given-names></string-name>, <string-name><surname>Sofer</surname><given-names>T.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Gharib</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Gottlieb</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>X.</given-names></string-name>, <string-name><surname>Lane</surname><given-names>J.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Whole-genome association analyses of sleep-disordered breathing phenotypes in the NHLBI TOPMed program</article-title>. <source>Genome Med.</source><year>2021</year>; <volume>13</volume>:<fpage>136</fpage>.<pub-id pub-id-type="pmid">34446064</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><collab>GTEx Consortium</collab><article-title>The GTEx Consortium atlas of genetic regulatory effects across human tissues</article-title>. <source>Science</source>. <year>2020</year>; <volume>369</volume>:<fpage>1318</fpage>–<lpage>1330</lpage>.<pub-id pub-id-type="pmid">32913098</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Leeuw</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Mooij</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Heskes</surname><given-names>T.</given-names></string-name>, <string-name><surname>Posthuma</surname><given-names>D</given-names></string-name></person-group><article-title>MAGMA: generalized gene-set analysis of GWAS data</article-title>. <source>PLoS Comput. Biol.</source><year>2015</year>; <volume>11</volume>:<fpage>e1004219</fpage>.<pub-id pub-id-type="pmid">25885710</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pei</surname><given-names>G.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Jia</surname><given-names>P.</given-names></string-name></person-group><article-title>deTS: tissue-specific enrichment analysis to decode tissue specificity</article-title>. <source>Bioinformatics</source>. <year>2019</year>; <volume>35</volume>:<fpage>3842</fpage>–<lpage>3845</lpage>.<pub-id pub-id-type="pmid">30824912</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barbeira</surname><given-names>A.N.</given-names></string-name>, <string-name><surname>Dickinson</surname><given-names>S.P.</given-names></string-name>, <string-name><surname>Bonazzola</surname><given-names>R.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wheeler</surname><given-names>H.E.</given-names></string-name>, <string-name><surname>Torres</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Torstenson</surname><given-names>E.S.</given-names></string-name>, <string-name><surname>Shah</surname><given-names>K.P.</given-names></string-name>, <string-name><surname>Garcia</surname><given-names>T.</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>T.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics</article-title>. <source>Nat. Commun.</source><year>2018</year>; <volume>9</volume>:<fpage>1825</fpage>.<pub-id pub-id-type="pmid">29739930</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname><given-names>K.</given-names></string-name>, <string-name><surname>Li</surname><given-names>L.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Teng</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Z.J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>D.</given-names></string-name></person-group><article-title>A comprehensive evaluation of connectivity methods for L1000 data</article-title>. <source>Brief Bioinform</source>. <year>2020</year>; <volume>21</volume>:<fpage>2194</fpage>–<lpage>2205</lpage>.<pub-id pub-id-type="pmid">31774912</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Struckmann</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ernst</surname><given-names>M.</given-names></string-name>, <string-name><surname>Fischer</surname><given-names>S.</given-names></string-name>, <string-name><surname>Mah</surname><given-names>N.</given-names></string-name>, <string-name><surname>Fuellen</surname><given-names>G.</given-names></string-name>, <string-name><surname>Moller</surname><given-names>S.</given-names></string-name></person-group><article-title>Scoring functions for drug-effect similarity</article-title>. <source>Brief Bioinform</source>. <year>2021</year>; <volume>22</volume>:<fpage>1</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">33401308</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Samart</surname><given-names>K.</given-names></string-name>, <string-name><surname>Tuyishime</surname><given-names>P.</given-names></string-name>, <string-name><surname>Krishnan</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ravi</surname><given-names>J.</given-names></string-name></person-group><article-title>Reconciling multiple connectivity scores for drug repurposing</article-title>. <source>Brief Bioinform</source>. <year>2021</year>; <volume>22</volume>:<fpage>1</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">33401308</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>T.</given-names></string-name>, <string-name><surname>Gindulyte</surname><given-names>A.</given-names></string-name>, <string-name><surname>He</surname><given-names>J.</given-names></string-name>, <string-name><surname>He</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Shoemaker</surname><given-names>B.A.</given-names></string-name>, <string-name><surname>Thiessen</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>PubChem 2023 update</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D1373</fpage>–<lpage>D1380</lpage>.<pub-id pub-id-type="pmid">36305812</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Webb</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Erdmann</surname><given-names>J.</given-names></string-name>, <string-name><surname>Stirrups</surname><given-names>K.E.</given-names></string-name>, <string-name><surname>Stitziel</surname><given-names>N.O.</given-names></string-name>, <string-name><surname>Masca</surname><given-names>N.G.</given-names></string-name>, <string-name><surname>Jansen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kanoni</surname><given-names>S.</given-names></string-name>, <string-name><surname>Nelson</surname><given-names>C.P.</given-names></string-name>, <string-name><surname>Ferrario</surname><given-names>P.G.</given-names></string-name>, <string-name><surname>Konig</surname><given-names>I.R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Systematic evaluation of pleiotropy identifies 6 further loci associated with coronary artery disease</article-title>. <source>J. Am. Coll. Cardiol.</source><year>2017</year>; <volume>69</volume>:<fpage>823</fpage>–<lpage>836</lpage>.<pub-id pub-id-type="pmid">28209224</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>Z.D.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>R.</given-names></string-name>, <string-name><surname>McDuffie</surname><given-names>M.</given-names></string-name>, <string-name><surname>Nadler</surname><given-names>J.L.</given-names></string-name></person-group><article-title>The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice</article-title>. <source>Diabetologia</source>. <year>2002</year>; <volume>45</volume>:<fpage>1307</fpage>–<lpage>1314</lpage>.<pub-id pub-id-type="pmid">12242464</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bursten</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Federighi</surname><given-names>D.</given-names></string-name>, <string-name><surname>Wald</surname><given-names>J.</given-names></string-name>, <string-name><surname>Meengs</surname><given-names>B.</given-names></string-name>, <string-name><surname>Spickler</surname><given-names>W.</given-names></string-name>, <string-name><surname>Nudelman</surname><given-names>E.</given-names></string-name></person-group><article-title>Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids</article-title>. <source>J. Pharmacol. Exp. Ther.</source><year>1998</year>; <volume>284</volume>:<fpage>337</fpage>–<lpage>345</lpage>.<pub-id pub-id-type="pmid">9435196</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beckman</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Creager</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Libby</surname><given-names>P.</given-names></string-name></person-group><article-title>Diabetes and atherosclerosis: epidemiology, pathophysiology, and management</article-title>. <source>JAMA</source>. <year>2002</year>; <volume>287</volume>:<fpage>2570</fpage>–<lpage>2581</lpage>.<pub-id pub-id-type="pmid">12020339</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Laurat</surname><given-names>E.</given-names></string-name>, <string-name><surname>Poirier</surname><given-names>B.</given-names></string-name>, <string-name><surname>Tupin</surname><given-names>E.</given-names></string-name>, <string-name><surname>Caligiuri</surname><given-names>G.</given-names></string-name>, <string-name><surname>Hansson</surname><given-names>G.K.</given-names></string-name>, <string-name><surname>Bariety</surname><given-names>J.</given-names></string-name>, <string-name><surname>Nicoletti</surname><given-names>A.</given-names></string-name></person-group><article-title>In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice</article-title>. <source>Circulation</source>. <year>2001</year>; <volume>104</volume>:<fpage>197</fpage>–<lpage>202</lpage>.<pub-id pub-id-type="pmid">11447086</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sumida</surname><given-names>T.S.</given-names></string-name>, <string-name><surname>Hafler</surname><given-names>D.A.</given-names></string-name></person-group><article-title>Population genetics meets single-cell sequencing</article-title>. <source>Science</source>. <year>2022</year>; <volume>376</volume>:<fpage>134</fpage>–<lpage>135</lpage>.<pub-id pub-id-type="pmid">35389792</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yazar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Alquicira-Hernandez</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wing</surname><given-names>K.</given-names></string-name>, <string-name><surname>Senabouth</surname><given-names>A.</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>M.G.</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Rowson</surname><given-names>A.</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>T.R.P.</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease</article-title>. <source>Science</source>. <year>2022</year>; <volume>376</volume>:<fpage>eabf3041</fpage>.<pub-id pub-id-type="pmid">35389779</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perez</surname><given-names>R.K.</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>M.G.</given-names></string-name>, <string-name><surname>Subramaniam</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kim</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Hartoularos</surname><given-names>G.C.</given-names></string-name>, <string-name><surname>Targ</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ogorodnikov</surname><given-names>A.</given-names></string-name>, <string-name><surname>Bueno</surname><given-names>R.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus</article-title>. <source>Science</source>. <year>2022</year>; <volume>376</volume>:<fpage>eabf1970</fpage>.<pub-id pub-id-type="pmid">35389781</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
